



(51) International Patent Classification:

C12Q 1/6886 (2018.01)

(21) International Application Number:

PCT/US2022/028579

(22) International Filing Date:

10 May 2022 (10.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/187,189 11 May 2021 (11.05.2021) US

(71) Applicant: JANUX THERAPEUTICS, INC. [US/US];
11099 North Torrey Pines Road, Suite 290, La Jolla, California 92037 (US).

(72) Inventors: CAMPBELL, David; 11099 North Torrey Pines Road, Suite 290, La Jolla, California 92037 (US).
DIRAIMONDO, Thomas R.; 11099 North Torrey Pines Road, Suite 290, La Jolla, California 92037 (US).

(74) Agent: MCNAMARA, Laurie K.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: ANTIBODIES TARGETING EGFR AND CD3 AND USES THEREOF




Fig. 1A

(57) Abstract: Provided herein are antibodies that selectively bind to EGFR and CD3, pharmaceutical compositions thereof, as well as methods of producing such antibodies.

ANTIBODIES TARGETING EGFR AND CD3 AND USES THEREOF**CROSS-REFERENCE**

[0001] The present application claims the benefit of U.S. Provisional Application No. 63/187,189, filed May 11, 2021, which is incorporated by reference in its entirety.

SUMMARY

[0002] Disclosed herein are isolated polypeptide complexes according to the following formula: A-L-B (Formula I) wherein A comprises a single chain variable fragment (scFv) that binds to CD3; B comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L comprises a linker that connects A to B. In some embodiments, the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21, LC-CDR2: SEQ ID NO: 22, and LC-CDR3: SEQ ID NO: 23, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3. In some embodiments, the scFv comprises a scFv light chain variable domain and a scFv heavy chain variable domain. In some embodiments, the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise either HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 3; or HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3. In some embodiments, the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise either LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8; or LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11 and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain

polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 25 or 27. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24 or 26. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 13 or 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 13 or 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence according to SEQ ID NO: 13 or 16. In some embodiments, the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 12 or 15. In some embodiments, the scFv light chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 12 or 15. In some embodiments, the scFv light chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15. In some embodiments, the scFv light chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15. In some embodiments, the scFv light chain variable domain comprises an amino acid sequence according to SEQ ID NO: 12 or 15. In some embodiments, the scFv comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 150 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17 and has at least 80% sequence identity to the at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv

comprises an amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the linker connects the C-terminus of A to an N-terminus of B. In some embodiments, the linker connects the N-terminus of A to a C-terminus of B. In some embodiments, the linker connects the C-terminus of A to the N-terminus of the Fab heavy chain polypeptide. In some embodiments, the linker connects the N-terminus of A to the C-terminus of the Fab heavy chain polypeptide. In some embodiments, the linker connects the C-terminus of A to the N-terminus of the Fab light chain polypeptide. In some embodiments, the linker connects the N-terminus of A to the C-terminus of the Fab light chain polypeptide. In some embodiments, the linker connects the Fab light chain polypeptide to the scFv light chain variable domain. In some embodiments, the linker connects the Fab light chain polypeptide to the scFv heavy chain variable domain. In some embodiments, the linker connects the Fab heavy chain polypeptide to the scFv light chain variable domain. In some embodiments, the linker connects the Fab heavy chain polypeptide to the scFv heavy chain variable domain. In some embodiments, the linker connects the Fab light chain polypeptide to the N-terminus of the scFv light chain variable domain. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain. In some embodiments, the linker connects the Fab light chain polypeptide to the N-terminus of the scFv heavy chain variable domain. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv heavy chain variable domain. In some embodiments, the linker connects the Fab heavy chain polypeptide to the N-terminus of the scFv light chain variable domain. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain. In some embodiments, the linker connects the Fab heavy chain polypeptide to the N-terminus of the scFv heavy chain variable domain. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv heavy chain variable domain. In some embodiments, the linker is at least 5 amino acids in length. In some embodiments, the linker is no more than 30 amino acids in length. In some embodiments, the linker is at least 5 amino acids and no more than 30 amino acids in length. In some embodiments, the linker is 5 amino acids in length. In some embodiments, the linker is 15 amino acids in length. In some embodiments, the linker comprises an amino acid sequence of SEQ ID NO: 28 (GGGSGGGSGGGGS), SEQ ID NO: 29 (GGGGS), or SEQ ID NO: 30 (GGGSGGGGS). In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 31. In

some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid

residues of SEQ ID NO: 32 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 33. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid

sequence according to SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 27 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 27 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 34.

[0003] Also disclosed herein are isolated polypeptide complexes according to the following formula: A-L-D (Formula II) wherein A comprises a single chain variable fragment (scFv) that binds to CD3; D comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L comprises a linker that connects the C-terminus of A to an N-terminus of D. In some embodiments, the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain. In some embodiments, the scFv comprises a scFv light chain variable domain and a scFv heavy chain variable domain. In some embodiments, the linker connects the C-terminus of A to the N-terminus of the Fab heavy chain polypeptide. In some embodiments, the linker connects the C-terminus of A to the N-terminus of the Fab light chain polypeptide. In some embodiments, the linker connects the C-terminus of the scFv light chain variable domain to the N-terminus of the Fab heavy chain polypeptide. In some embodiments, the linker connects the C-terminus of scFv light chain variable domain to the N-terminus of the Fab light chain polypeptide. In some embodiments, the linker connects the C-terminus of the scFv heavy chain variable domain to the N-terminus of the Fab heavy chain polypeptide. In some embodiments, the linker connects the C-terminus of scFv heavy chain variable domain to the N-terminus of the Fab light chain polypeptide. In some embodiments, the Fab heavy chain variable

domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3. In some embodiments, the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21; LC-CDR2: SEQ ID NO: 22; and LC-CDR3: SEQ ID NO: 23, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3. In some embodiments, the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: either HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, HC-CDR3: SEQ ID NO: 3; or HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3. In some embodiments, the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise either LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8; or LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 25 or 27. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence according

to SEQ ID NO: 24 or 26. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 13 or 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 13 or 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence according to SEQ ID NO: 13 or 16. In some embodiments, the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 12 or 15. In some embodiments, the scFv light chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 12 or 15. In some embodiments, the scFv light chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15. In some embodiments, the scFv light chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15. In some embodiments, the scFv light chain variable domain comprises an amino acid sequence according to SEQ ID NO: 12 or 15. In some embodiments, the scFv comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 150 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17 and has at least 80% sequence identity to the at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the linker is at least 5 amino acids in length. In some embodiments, the linker is no more than 30 amino acids in length. In some embodiments, the linker is at least 5 amino acids and no more than 30 amino acids in length. In some embodiments, the linker is 5 amino acids in length. In some embodiments, the linker is 15 amino acids in length. In some embodiments, the linker comprises an amino acid sequence of SEQ ID NO: 28 (GGGGSGGGSGGGGS), SEQ ID NO: 29 (GGGGS), or SEQ ID NO: 30 (GGGGSGGGGS). In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain

polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv heavy chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv heavy chain variable domain comprises an amino acid sequence of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain

variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv heavy chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 33. In some embodiments, the linker connects the Fab

light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light heavy polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 27 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 27 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 34.

[0004] Additionally disclosed herein are pharmaceutical compositions comprising: the isolated polypeptide complex according to any embodiment herein; and a pharmaceutically acceptable excipient.

[0005] Further disclosed herein are isolated recombinant nucleic acid molecules encoding a polypeptide of the polypeptide complex according to any embodiment herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0006] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0007] **Figs. 1A-1B** illustrate exemplary configurations of an antibody that selectively binds to EGFR and CD3. **Fig. 1A** exemplifies a Fab that binds to EGFR and a scFv that binds to CD3 in which the N-terminus

of the Fab heavy chain polypeptide is connected by a linker to the C-terminus of the scFv light chain variable domain. **Fig. 1B** exemplifies a Fab that binds to EGFR and a scFv that binds to CD3 in which the N-terminus of the Fab light chain polypeptide is connected by a linker to the C-terminus scFv light chain variable domain.

[0008] **Fig. 2** illustrates Ab-1 and Ab-2 binding to EGFR measured by ELISA.

[0009] **Fig. 3** illustrates Ab-3 binding to EGFR measured by ELISA.

[0010] **Fig. 4** illustrates Ab-1 and Ab-2 binding to CD3 measured by ELISA.

[0011] **Fig. 5** illustrates Ab-3 binding to CD3 measured by ELISA.

[0012] **Fig. 6** illustrates Ab-1 kinetic binding and cross reactivity against human and cynomolgus monkey EGFR.

[0013] **Fig. 7** illustrates Ab-1 kinetic binding and cross reactivity against human and cynomolgus monkey CD3.

[0014] **Fig. 8** illustrates Ab-1 and Ab-2 equilibrium binding against human EGFR.

[0015] **Fig. 9** illustrates Ab-1 and Ab-2 equilibrium binding against cyno EGFR.

[0016] **Fig. 10** illustrates Ab-1 and Ab-2 equilibrium binding against human CD3.

[0017] **Fig. 11** illustrates Ab-1 and Ab-2 equilibrium binding against cyno CD3.

[0018] **Fig. 12** illustrates Ab-3 mediated HCT116 tumor killing in the presence of CD8+ T cells.

[0019] **Fig. 13** illustrates Ab-2 mediated HCT116 tumor killing in the presence of CD8+ T cells.

[0020] **Fig. 14** illustrates Ab-1 mediated HCT116 tumor killing in the presence of CD8+ T cells.

[0021] **Fig. 15** illustrates Ab-1 mediated A431 tumor killing in the presence of CD8+ T cells.

[0022] **Fig. 16** illustrates Ab-3 pharmacokinetics in cynomolgus monkeys after a single IV bolus injection.

[0023] **Fig. 17** illustrates cytokine release in cynomolgus monkeys after single IV bolus of Ab-3.

[0024] **Fig. 18** illustrates serum liver enzymes in cynomolgus monkeys after single IV bolus of Ab-3.

[0025] **Fig. 19** illustrates Ab-1 and Ab-4 binding to EGFR measured by ELISA.

[0026] **Fig. 20** illustrates Ab-1 and Ab-4 binding to CD3 ϵ measured by ELISA.

[0027] **Fig. 21** illustrates Ab-1 and Ab-4 mediated HCT116 tumor cell killing in the presence of CD8+ T cells.

[0028] **Fig. 22** illustrates pharmacokinetics in cynomolgus monkeys after continuous IV infusion of Ab-1.

[0029] **Figs. 23A-23B** illustrate cytokine release in cynomolgus monkeys after continuous IV infusion of Ab-1.

DETAILED DESCRIPTION

[0030] Multispecific antibodies combine the benefits of different binding specificities derived from two or more antibodies into a single composition. Multispecific antibodies for redirecting T cells to cancers have shown promise in both pre-clinical and clinical studies. This approach relies on binding of one antigen interacting portion of the antibody to a tumor-associated antigen or marker, while a second antigen interacting portion can bind to an effector cell antigen on a T cell, such as CD3, which then triggers cytotoxic activity.

[0031] One such tumor-associated antigen is EGFR. Epidermal growth factor receptor (EGFR), also known as ERBB1, receptor tyrosine-protein kinase ErbB-1, or proto-oncogene C ErbB-1 is a transmembrane glycoprotein that is a member of the protein kinase superfamily. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing receptor dimerization and tyrosine autophosphorylation leading to cell proliferation. Amplification and mutations in EGFR have been shown to be driving events in many cancer types.

[0032] Disclosed herein are antibodies that selectively bind to EGFR and CD3, in which the anti-EGFR domain is in a Fab or Fab' antibody format that is linked to a single-chain variable fragment (scFv) that binds to CD3. The bispecific antibody format of a Fab or Fab' linked to a scFv provides efficacy and safety advantages over other bispecific antibody formats. In some embodiments, the Fab or Fab' comprises a Fab light chain polypeptide comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise either HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20; and wherein said CDRs comprise from 0-2 amino acid modifications in at least one of said HC-CDR1, HC-CDR2, or HC-CDR3. In some embodiments, the scFv that binds to CD3 is linked to an N-terminus of the Fab or Fab' that binds to EGFR.

[0033] In some embodiments, the antibodies described herein are used in a method of treating cancer. In some embodiments, the cancer has cells that express EGFR. In some instances, the cancer is a solid tumor cancer. In some embodiments, the cancer is colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), non-small-cell lung carcinoma (NSCLC), prostate cancer, breast cancer (e.g. HER2+; ER/PR+; TNBC), esophagogastric cancer, liver cancer, glioblastoma, cervical cancer, ovarian cancer, bladder cancer, kidney cancer, or pancreatic cancer.

Certain Definitions

[0034] The terminology used herein is for the purpose of describing particular cases only and is not intended to be limiting. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms "including", "includes", "having", "has", "with", or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term "comprising."

[0001] The term "antibody" is used in the broadest sense and covers fully assembled antibodies, antibody fragments that can bind antigen, for example, Fab, F(ab')₂, Fv, single chain antibodies (scFv), diabodies, antibody chimeras, hybrid antibodies, bispecific antibodies, and the like.

[0002] The term "complementarity determining region" or "CDR" is a segment of the variable region of an antibody that is complementary in structure to the epitope to which the antibody binds and is more variable than the rest of the variable region. Accordingly, a CDR is sometimes referred to as hypervariable region. A variable region comprises three CDRs. CDR peptides can be obtained by constructing genes encoding the

CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick et al., *Methods: A Companion to Methods in Enzymology* 2: 106 (1991); Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies," in *Monoclonal Antibodies: Production, Engineering and Clinical Application*, Ritter et al. (eds.), pages 166-179 (Cambridge University Press 1995); and Ward et al., "Genetic Manipulation and Expression of Antibodies," in *Monoclonal Antibodies: Principles and Applications*, Birch et al., (eds.), pages 137-185 (Wiley-Liss, Inc. 1995).

[0003] The term "Fab" refers to a protein that contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. Fab' fragments are produced by reducing the F(ab')₂ fragment's heavy chain disulfide bridge. Other chemical couplings of antibody fragments are also known.

[0004] A "single-chain variable fragment (scFv)" is a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of an antibody, connected with a short linker peptide of ten to about 25 amino acids. The linker is usually rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the VH with the C-terminus of the VL, or vice versa. This protein retains the specificity of the original antibody, despite removal of the constant regions and the introduction of the linker. scFv antibodies are, e.g. described in Houston, J. S., *Methods in Enzymol.* 203 (1991) 46-96). In addition, antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain, namely being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the antigen binding property of full length antibodies.

[0005] As used herein, the term "percent (%) amino acid sequence identity" with respect to a sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as EMBOSS MATCHER, EMBOSS WATER, EMBOSS STRETCHER, EMBOSS NEEDLE, EMBOSS LALIGN, BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.

[0006] In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the

fraction X/Y , where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B , and where Y is the total number of amino acid residues in B . It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B , the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A . Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[0007] The terms “complementarity determining region,” and “CDR,” which are synonymous with “hypervariable region” or “HVR,” are known in the art to refer to non-contiguous sequences of amino acids within antibody variable regions, which confer antigen specificity and/or binding affinity. In general, there are three CDRs in each heavy chain variable region (CDR-H1, CDR-H2, CDR-H3) and three CDRs in each light chain variable region (CDR-L1, CDR-L2, CDR-L3). “Framework regions” and “FR” are known in the art to refer to the non-CDR portions of the variable regions of the heavy and light chains. In general, there are four FRs in each full-length heavy chain variable region (FR-H1, FR-H2, FR-H3, and FR-H4), and four FRs in each full-length light chain variable region (FR-L1, FR-L2, FR-L3, and FR-L4). The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 (“Chothia” numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), “Antibody-antigen interactions: Contact analysis and binding site topography,” J. Mol. Biol. 262, 732-745.” (“Contact” numbering scheme); Lefranc MP et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol, 2003 Jan;27(1):55-77 (“IMGT” numbering scheme); Honegger A and Plückthun A, “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” J Mol Biol, 2001 Jun 8;309(3):657-70, (“Aho” numbering scheme); and Whitelegg NR and Rees AR, “WAM: an improved algorithm for modelling antibodies on the WEB,” Protein Eng. 2000 Dec;13(12):819-24 (“AbM” numbering scheme). In certain embodiments the CDRs of the antibodies described herein can be defined by a method selected from Kabat, Chothia, IMGT, Aho, AbM, or combinations thereof.

[0008] The boundaries of a given CDR or FR may vary depending on the scheme used for identification. For example, the Kabat scheme is based on structural alignments, while the Chothia scheme is based on structural information. Numbering for both the Kabat and Chothia schemes is based upon the most common antibody region sequence lengths, with insertions accommodated by insertion letters, for example, “30a,” and deletions appearing in some antibodies. The two schemes place certain insertions and deletions (“indels”) at different positions, resulting in differential numbering. The Contact scheme is based on analysis of complex crystal structures and is similar in many respects to the Chothia numbering scheme.

[0009] Disclosed herein are isolated polypeptide complexes according to the following formula:

A-L-B

(Formula I)

wherein A comprises a single chain variable fragment (scFv) that binds to CD3; and B comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L comprises a linker that connects A to B. Disclosed herein are isolated polypeptide complexes comprising the following formula:

A-L-B

(Formula I)

wherein A comprises a single chain variable fragment (scFv) that binds to CD3; and B comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L comprises a linker that connects A to B. Disclosed herein are isolated polypeptide complexes comprising the following formula:

A-L-B

(Formula I)

wherein A is a single chain variable fragment (scFv) that binds to CD3; and B is an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L is a linker that connects A to B. Disclosed herein are isolated polypeptide complexes according to the following formula:

A-L-B

(Formula I)

wherein A is a single chain variable fragment (scFv) that binds to CD3; and B is an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide chain

comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L is a linker that connects A to B.

[0010] Disclosed herein are isolated polypeptide complexes according to the following formula:

A-L-D
(Formula II)

wherein A comprises a single chain variable fragment (scFv) that binds to CD3; D comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L comprises a linker that connects the C-terminus of A to an N-terminus of D. Disclosed herein are isolated polypeptide complexes comprising the following formula:

A-L-D
(Formula II)

wherein A comprises a single chain variable fragment (scFv) that binds to CD3; D comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L comprises a linker that connects the C-terminus of A to an N-terminus of D. Disclosed herein are isolated polypeptide complexes comprising the following formula:

A-L-D
(Formula II)

wherein A is a single chain variable fragment (scFv) that binds to CD3; D is an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L is a linker that connects the C-terminus of A to an N-terminus of D. Disclosed herein are isolated polypeptide complexes according to the following formula:

A-L-D
(Formula II)

wherein A is a single chain variable fragment (scFv) that binds to CD3; D is an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L is a linker that connects the C-terminus of A to an N-terminus of D.

Single chain variable fragments (scFv) that bind to CD3

[0011] In some embodiments, the scFv that binds to CD3 comprises a scFv light chain variable domain and a scFv heavy chain variable domain. In some embodiments, the scFv heavy chain variable domain comprises at least one, two, or three complementarity determining regions (CDR)s disclosed in **Table 1** or a sequence substantially identical thereto (e.g., a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity). In some embodiments, the scFv light chain variable domain comprises at least one, two, or three complementarity determining regions (CDR)s disclosed in **Table 2** or a sequence substantially identical thereto (e.g., a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity).

[0012] In some embodiments, the scFv heavy chain variable domain comprises at least one, two, or three complementarity determining regions (CDRs) disclosed in **Table 1** or a sequence substantially identical thereto (e.g., a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity); and the scFv light chain variable domain comprises at least one, two, or three complementarity determining regions (CDRs) disclosed in **Table 2** or a sequence substantially identical thereto (e.g., a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity).

[0013] In some embodiments, the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise either HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 3; or HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3. In some embodiments, the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise either LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8; or LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

[0014] In some embodiments, the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: either HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 3; or HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise: either LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8; or LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11 and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3. In some embodiments, the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 3; and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise: LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8; and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3. In some embodiments, the scFv heavy chain variable

domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 4; HC-CDR2: SEQ ID NO: 2; HC-CDR3: SEQ ID NO: 5, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise: LC-CDR1: SEQ ID NO: 9; LC-CDR2: SEQ ID NO: 10; and LC-CDR3: SEQ ID NO: 11, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

[0015] In some embodiments, the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise HC-CDR1 either HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 3; or HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5. In some embodiments, the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 1; HC-CDR2: SEQ ID NO: 2; HC-CDR3: SEQ ID NO: 3. In some embodiments, the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 4; HC-CDR2: SEQ ID NO: 2; HC-CDR3: SEQ ID NO: 5. In some embodiments, the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise either LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8, or LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11. In some embodiments, the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise: LC-CDR1: SEQ ID NO: 6; LC-CDR2: SEQ ID NO: 7; and LC-CDR3: SEQ ID NO: 8. In some embodiments, the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise: LC-CDR1: SEQ ID NO: 9; LC-CDR2: SEQ ID NO: 10; and LC-CDR3: SEQ ID NO: 11.

[0016] In some embodiments, the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1 either HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 3; or HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5; and the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2,

and the LC-CDR3 of the scFv light chain variable domain comprise either LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8; or LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11. In some embodiments, the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 1; HC-CDR2: SEQ ID NO: 2; HC-CDR3: SEQ ID NO: 3; and the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise: LC-CDR1: SEQ ID NO: 6; LC-CDR2: SEQ ID NO: 7; and LC-CDR3: SEQ ID NO: 8. In some embodiments, the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 4; HC-CDR2: SEQ ID NO: 2; HC-CDR3: SEQ ID NO: 5; and the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise: LC-CDR1: SEQ ID NO: 9; LC-CDR2: SEQ ID NO: 10; and LC-CDR3: SEQ ID NO: 11.

Table 1. anti-CD3 scFv heavy chain variable domain complementarity determining regions (CDRs) (as based on the IMGT CDR numbering system).

Construct Description	Amino Acid Sequence (N to C)	SEQ ID NO:
CD3 1: CDR-H1	GFTFNKYA	1
CD3 1: CDR-H2	IRSKYNNYAT	2
CD3 1: CDR-H3	VRHGNFGNSYISYWAY	3
CD3 2: CDR-H1	GFTFNTYA	4
CD3 2: CDR-H2	IRSKYNNYAT	2
CD3 2: CDR-H3	VRHGNFGNSYVSWFAY	5

Table 2. anti-CD3 scFv light chain variable domain complementarity determining regions (CDRs) (as based on the IMGT CDR numbering system).

Construct Description	Amino Acid Sequence (N to C)	SEQ ID NO:
CD3 1: CDR-L1	TGAVTSGNY	6
CD3 1: CDR-L2	GTK	7
CD3 1: CDR-L3	VLWYSNRWV	8
CD3 2: CDR-L1	TGAVTTSNY	9

CD3 2: CDR-L2	GTN	10
CD3 2: CDR-L3	ALWYSNLWV	11

[0017] In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 70% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 85% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 90% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 91% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 92% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 93% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 94% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 95% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 96% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 97% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence according to SEQ ID NO: 13 OR 16.

[0018] In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 60 consecutive amino acid residues of SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 70 consecutive amino acid residues of SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 80 consecutive amino acid residues of SEQ ID NO: 13 OR 16. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence of at least 90 consecutive amino acid residues of SEQ ID NO: 13 OR 16. In some

[illegible]

[illegible]

[0030] In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 70% sequence identity to the amino acid sequence according to SEQ ID NO: 16; and the scFv light chain variable domain comprises an amino acid sequence that has at least 70% sequence identity to the amino

[illegible]

that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 15. In some embodiments, the scFv heavy chain variable domain comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 16; and the scFv light chain variable domain comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 15.

[0031] In some embodiments, the scFv comprises an amino acid sequence that has at least 70% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence that has at least 85% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence that has at least 90% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence that has at least 91% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence that has at least 92% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence that has at least 93% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence that has at least 94% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence that has at least 95% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence that has at least 96% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence that has at least 97% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence according to SEQ ID NO: 14 or 17.

[0032] In some embodiments, the scFv comprises an amino acid sequence of at least 150 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 175 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 220 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 230 consecutive amino acid residues of

embodiments, the scFv comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 14 or 17, and has at least 99% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 14 or 17, and has at least 99% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 220 consecutive amino acid residues of SEQ ID NO: 14 or 17, and has at least 99% sequence identity to the at least 220 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17, and has at least 99% sequence identity to the at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 230 consecutive amino acid residues of SEQ ID NO: 14 or 17, and has at least 99% sequence identity to the at least 230 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 235 consecutive amino acid residues of SEQ ID NO: 14 or 17, and has at least 99% sequence identity to the at least 235 consecutive amino acid residues of SEQ ID NO: 14 or 17. In some embodiments, the scFv comprises an amino acid sequence of at least 240 consecutive amino acid residues of SEQ ID NO: 14 or 17, and has at least 99% sequence identity to the at least 240 consecutive amino acid residues of SEQ ID NO: 14 or 17.

Table 3. anti-CD3 scFv light chain variable domain, heavy chain variable domain sequences, and full length sequence

Construct Description	Amino Acid Sequence (N to C)	SEQ ID NO:
CD3 1 scFv: LC	QTVVTQEPSTLVSPGGTVTLT CGSSTGAVTSGNYPNWWQK PGQAPRGLIGGTKFLAPGTPA RFGSLLGGKAALTLSGVQPE DEAEYYCVLWYSNRWVFGG GTKLTVL	12
CD3 1 scFv: HC	EVQLVESGGGLVQPGGSLKLS CAASGFTFNKYAMNWVRQA PGKGLEWVARIRSKYNNYAT YYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYWGQGTLV TVSS	13
CD3 1 scFv	EVQLVESGGGLVQPGGSLKLS CAASGFTFNKYAMNWVRQA PGKGLEWVARIRSKYNNYAT YYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYWGQGTLV TVSSGGGGSGGGSGGGGSQT VVTQEPSTLVSPGGTVTLTCGS STGAVTSGNYPNWWQKPGQ APRGLIGGTKFLAPGTPARFSG SLLGGKAALTLSGVQPEDEAE	14

	YYC <u>VLWYSNRWV</u> FGGGTKLTVL	
CD3 2 scFv VL	QTVVTQEPSTVSPGGTVTLT CRSSTGAVTTSNYANWVQQK PGQAPRGLIGGTNKRAPGTPA RFGSLLGGKAALTLSGVQPE DEAEYYC <u>ALWYSNLWV</u> FGG GTKLTVL	15
CD3 2 scFv VH	EVQLVESGGGLVQPGGSLKLS CAASGFTFNTYAMNWVRQAP GKGLEWVARIRSKYNNYATY YADSVKDRFTISRDDSKNTAY LQMNNLKTEDTAVYYC <u>VRHG</u> <u>NFGNSYVSWFAY</u> WGQGTLLVTVSS	16
CD3 2 scFv	QTVVTQEPSTVSPGGTVTLT CRSSTGAVTTSNYANWVQQK PGQAPRGLIGGTNKRAPGTPA RFGSLLGGKAALTLSGVQPE DEAEYYC <u>ALWYSNLWV</u> FGG GTKLTVLGGGGSGGGSGGG GSEVQLVESGGGLVQPGGSLK LSCAASGFTFNTYAMNWVRQ APGKGLEWVARIRSKYNNYA <u>TY</u> YADSVKDRFTISRDDSKNT AYLQMNNLKTEDTAVYYC <u>VR</u> <u>HGNF</u> GNSYVSWFAYWGQGT LTVTVSS	17

Antigen binding fragment (Fab) or Fab' that bind to EGFR

[0037] In some embodiments, the antigen binding fragment (Fab) or Fab' that binds to EGFR comprises a Fab light chain polypeptide chain and a Fab heavy chain polypeptide. In some embodiments, the Fab light chain polypeptide comprises a Fab light chain variable domain. In some embodiments, the Fab heavy chain polypeptide comprises a Fab heavy chain variable domain. In some embodiments, the Fab heavy chain variable domain comprises at least one, two, or three complementarity determining regions (CDR)s disclosed in **Table 4** or a sequence substantially identical thereto (e.g., a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity). In some embodiments, the Fab light chain variable domain comprises at least one, two, or three complementarity determining regions (CDR)s disclosed in **Table 5** or a sequence substantially identical thereto (e.g., a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity).

[0038] In some embodiments, the Fab heavy chain variable domain comprises at least one, two, or three complementarity determining regions (CDR)s disclosed in **Table 4** or a sequence substantially identical thereto (e.g., a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity); and the Fab light chain variable domain comprises at least one, two, or three complementarity determining regions (CDR)s disclosed in **Table 5** or a sequence substantially identical thereto (e.g., a sequence that has at least 90%, 95%, 96%, 97%, 98%, or 99% sequence identity).

[0039] In some embodiments, the Fab heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3. In some embodiments, the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21, LC-CDR2: SEQ ID NO: 22, and LC-CDR3: SEQ ID NO: 23, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

[0040] In some embodiments, the Fab heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21, LC-CDR2: SEQ ID NO: 22, and LC-CDR3: SEQ ID NO: 23, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

[0041] In some embodiments, the Fab heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20; and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise: LC-CDR1: SEQ ID NO: 21, LC-CDR2: SEQ ID NO: 22, and LC-CDR3: SEQ ID NO: 23 and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

[0042] In some embodiments, the Fab heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20. In some embodiments, the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21, LC-CDR2: SEQ ID NO: 22, and LC-CDR3: SEQ ID NO: 23.

[0043] In some embodiments, the Fab heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID

NO: 19, and HC-CDR3: SEQ ID NO: 20; and the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21, LC-CDR2: SEQ ID NO: 22, and LC-CDR3: SEQ ID NO: 23.

[0044] In some embodiments, the Fab heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20 and the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise: LC-CDR1: SEQ ID NO: 21, LC-CDR2: SEQ ID NO: 22, and LC-CDR3: SEQ ID NO: 23.

Table 4. anti- EGFR Fab heavy chain variable domain complementarity determining regions (CDR)s (as based on the IMGT CDR numbering system).

Construct Description	Amino Acid Sequence (N to C)	SEQ ID NO:
EGFR 1: CDR-H1	GFSLTNYG	18
EGFR 1: CDR-H2	IWSGGNT	19
EGFR 1: CDR-H3	ARALTYDYEFAY	20

Table 5. anti- EGFR Fab light chain variable domain complementarity determining regions (CDR)s (as based on the IMGT CDR numbering system).

Construct Description	Amino Acid Sequence (N to C)	SEQ ID NO:
EGFR 1: CDR-L1	QSIGTN	21
EGFR 1: CDR-L2	YAS	22
EGFR 1: CDR-L3	QQNNNWPTT	23

[0045] In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 70% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 85% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 90% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 91% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an

amino acid residues of SEQ ID NO: 25 or 27, and has at least 95% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 25 or 27, and has at least 95% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 215 consecutive amino acid residues of SEQ ID NO: 25 or 27, and has at least 95% sequence identity to the at least 215 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 220 consecutive amino acid residues of SEQ ID NO: 25 or 27, and has at least 95% sequence identity to the at least 220 consecutive amino acid residues of SEQ ID NO: 25 or 27.

[0050] In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 25 or 27, and has at least 99% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 150 consecutive amino acid residues of SEQ ID NO: 25 or 27, and has at least 99% sequence identity to the at least 150 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 175 consecutive amino acid residues of SEQ ID NO: 25 or 27, and has at least 99% sequence identity to the at least 175 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27, and has at least 99% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 25 or 27, and has at least 99% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 25 or 27.

[0051] In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 215 consecutive amino acid residues of SEQ ID NO: 25 or 27, and has at least 99% sequence identity to the at least 215 consecutive amino acid residues of SEQ ID NO: 25 or 27. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence of at least 220 consecutive amino acid residues of SEQ ID NO: 25 or 27, and has at least 99% sequence identity to the at least 220 consecutive amino acid residues of SEQ ID NO: 25 or 27.

[0052] In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence that has at least 70% sequence identity to the amino acid sequence according to SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence that has at least 85% sequence identity to the amino acid sequence according to SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence that has at least 90% sequence identity to the amino acid

sequence identity to the at least 175 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 190 consecutive amino acid residues of SEQ ID NO: 24 or 26, and has at least 95% sequence identity to the at least 190 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26, and has at least 95% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 205 consecutive amino acid residues of SEQ ID NO: 24 or 26, and has at least 95% sequence identity to the at least 205 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 24 or 26, and has at least 95% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 24 or 26.

[0057] In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 or 26, and has at least 99% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 150 consecutive amino acid residues of SEQ ID NO: 24 or 26, and has at least 99% sequence identity to the at least 150 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 175 consecutive amino acid residues of SEQ ID NO: 24 or 26, and has at least 99% sequence identity to the at least 175 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 190 consecutive amino acid residues of SEQ ID NO: 24 or 26, and has at least 99% sequence identity to the at least 190 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26, and has at least 99% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 205 consecutive amino acid residues of SEQ ID NO: 24 or 26, and has at least 99% sequence identity to the at least 205 consecutive amino acid residues of SEQ ID NO: 24 or 26. In some embodiments, the Fab light chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 24 or 26, and has at least 99% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 24 or 26.

[0058] In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 70% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27; and the Fab light chain polypeptide comprises an amino acid sequence that has at least 70% sequence identity to the amino acid sequence according to SEQ ID NO: 24 or 26. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27; and the Fab light chain polypeptide comprises an amino acid sequence

[illegible]

sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27; and the Fab light chain polypeptide comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 24 or 26.

[illegible]

acid sequence that has at least 97% sequence identity to the amino acid sequence according to SEQ ID NO: 25; and the Fab light chain polypeptide comprises an amino acid sequence that has at least 97% sequence identity to the amino acid sequence according to SEQ ID NO: 24. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 25; and the Fab light chain polypeptide comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 24. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 25; and the Fab light chain polypeptide comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 24.

[illegible]

polypeptide comprises an amino acid sequence that has at least 95% sequence identity to the amino acid sequence according to SEQ ID NO: 27; and the Fab light chain polypeptide comprises an amino acid sequence that has at least 95% sequence identity to the amino acid sequence according to SEQ ID NO: 26. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 96% sequence identity to the amino acid sequence according to SEQ ID NO: 27; and the Fab light chain polypeptide comprises an amino acid sequence that has at least 96% sequence identity to the amino acid sequence according to SEQ ID NO: 26. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 97% sequence identity to the amino acid sequence according to SEQ ID NO: 27; and the Fab light chain polypeptide comprises an amino acid sequence that has at least 97% sequence identity to the amino acid sequence according to SEQ ID NO: 26. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 27; and the Fab light chain polypeptide comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 26. In some embodiments, the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 27; and the Fab light chain polypeptide comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 26.

Table 6. anti-EGFR Fab light chain polypeptide and Fab heavy chain polypeptide sequences

Construct Description	Amino Acid Sequence (N to C)	SEQ ID NO:
EGFR 1 Fab LC	QILLTQSPVILSVSPGERVSFSC RASQSIGTNIHWYQQRNGSP RLLIK Y ASESISGIPSRFSGSGS GTDFTLSINSVESEDIADYYCQ QNNNWPTTFGAGTKLELKRT VAAPSVFIFPPSDEQLKSGTAS VVCLLNFPYPREAKVQWKVD NALQSGNSQESVTEQDSKDST YLSSTLTLSKADYEKHKVYA CEVTHQQLSSPVTKSFNRGEC	24
EGFR 1 Fab HC	QVQLKQSGPGLVQPQSLSITC TVSGFSLTNYGVHWVRQSPG KGLEWLGVIWGGNTDYNT FTSRLSINKDNSKSQVFFKMNS LQSNDAIYYCARALTYDY EFAYWGQGTLLTVSAASTKG PSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSC	25
EGFR 2 Fab LC	DILLTQSPVILSVSPGERVSFSC RASQSIGTNIHWYQQRNGSP	26

	RLLIKYASESISGIPSRFSGSGS GTDFTLSINSVESEDIADYYCQ QNNNWPTTFGAGTKLELKRT VAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDST YLSSTLTLSKADYEKHKVYA CEVTHQGLSSPVTKSFNRGEC	
EGFR 2 Fab HC	QVQLKQSGPGLVQPSQSLITC TVSGFSLTNYGVHWVRQSPG KGLEWLGVIWSGGNTDYNTP FTSRLSINKDNSKSQVFFKMNS LQSQDTAIYYCARALTYDY EFAYWGQGTLLTVSAASTKG PSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSC	27

Linker

[0061] In some embodiments, the linker is at least 5 amino acids in length. In some embodiments, the linker is no more than 30 amino acids in length. In some embodiments, the linker is at least 5 amino acids and no more than 30 amino acids in length. In some embodiments, the linker is 5 amino acids in length. In some embodiments, the linker is 6 amino acids in length. In some embodiments, the linker is 7 amino acids in length. In some embodiments, the linker is 8 amino acids in length. In some embodiments, the linker is 9 amino acids in length. In some embodiments, the linker is 10 amino acids in length. In some embodiments, the linker is 11 amino acids in length. In some embodiments, the linker is 12 amino acids in length. In some embodiments, the linker is 13 amino acids in length. In some embodiments, the linker is 14 amino acids in length. In some embodiments, the linker is 15 amino acids in length. In some embodiments, the linker is 16 amino acids in length. In some embodiments, the linker is 17 amino acids in length. In some embodiments, the linker is 18 amino acids in length. In some embodiments, the linker is 19 amino acids in length. In some embodiments, the linker is 20 amino acids in length. In some embodiments, the linker is 21 amino acids in length. In some embodiments, the linker is 22 amino acids in length. In some embodiments, the linker is 23 amino acids in length. In some embodiments, the linker is 24 amino acids in length. In some embodiments, the linker is 25 amino acids in length. In some embodiments, the linker is 26 amino acids in length. In some embodiments, the linker is 27 amino acids in length. In some embodiments, the linker is 28 amino acids in length. In some embodiments, the linker is 29 amino acids in length. In some embodiments, the linker is 30 amino acids in length. In some embodiments, the linker comprises an amino acid sequence of SEQ ID NO: 28 (GGGGSGGGSGGGGS), SEQ ID NO: 29 (GGGGS), or SEQ ID NO: 30 (GGGGSGGGGS). In some embodiments, the linker comprises an amino acid sequence of SEQ ID NO: 28 (GGGGSGGGSGGGGS). In some embodiments, the linker comprises an amino acid sequence of SEQ ID NO: 29 (GGGGS). In some embodiments, the linker comprises an amino acid sequence of SEQ ID NO: 30 (GGGGSGGGGS).

[0062] In some embodiments, the linker connects the C-terminus of A to an N-terminus of B. In some embodiments, the linker connects the N-terminus of A to a C-terminus of B. In some embodiments, the linker connects the C-terminus of A to the N-terminus of the Fab heavy chain polypeptide. In some embodiments, the linker connects the N-terminus of A to the C-terminus of the Fab heavy chain polypeptide. In some embodiments, the linker connects the C-terminus of A to the N-terminus of the Fab light chain polypeptide. In some embodiments, the linker connects the N-terminus of A to the C-terminus of the Fab light chain polypeptide. In some embodiments, the linker connects the Fab light chain polypeptide to the scFv light chain variable domain. In some embodiments, the linker connects the Fab light chain polypeptide to the scFv heavy chain variable domain. In some embodiments, the linker connects the Fab heavy chain polypeptide to the scFv light chain variable domain. In some embodiments, the linker connects the Fab heavy chain polypeptide to the scFv heavy chain variable domain. In some embodiments, the linker connects the Fab light chain polypeptide to the N-terminus of the scFv light chain variable domain. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain. In some embodiments, the linker connects the Fab light chain polypeptide to the N-terminus of the scFv heavy chain variable domain. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv heavy chain variable domain. In some embodiments, the linker connects the Fab heavy chain polypeptide to the N-terminus of the scFv light chain variable domain. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain. In some embodiments, the linker connects the Fab heavy chain polypeptide to the N-terminus of the scFv heavy chain variable domain. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv heavy chain variable domain.

[0063] In some embodiments, the linker that connects the C-terminus of A to an N-terminus of D. In some embodiments, the linker connects the C-terminus of A to the N-terminus of the Fab heavy chain polypeptide. In some embodiments, the linker connects the C-terminus of A to the N-terminus of the Fab light chain polypeptide. In some embodiments, the linker connects the C-terminus of the scFv light chain variable domain to the N-terminus of the Fab heavy chain polypeptide. In some embodiments, the linker connects the C-terminus of scFv light chain variable domain to the N-terminus of the Fab light chain polypeptide. In some embodiments, the linker connects the C-terminus of the scFv heavy chain variable domain to the N-terminus of the Fab heavy chain polypeptide. In some embodiments, the linker connects the C-terminus of scFv heavy chain variable domain to the N-terminus of the Fab light chain polypeptide.

Table 7. Linker sequences

Construct Description	Amino Acid Sequence (N to C)	SEQ ID NO:
Linker	GGGSGGGSGGGGS	28
Linker	GGGGS	29
Linker	GGGSGGGGS	30

Antibodies that bind to EGFR and CD3

[illegible]

variable domain comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 31.

[0065] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 31.

[0066] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 31 and has at least 80% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at

least 470 consecutive amino acid residues of SEQ ID NO: 31 and has at least 80% sequence identity to the at least 470 consecutive amino acid residues of SEQ ID NO: 31.

[0067] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 and has at least 90% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 31 and has at least 90% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 90% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31 and has at least 90% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 24 and has at least 90% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 31 and has at least 90% sequence identity to the at least 470 consecutive amino acid residues of SEQ ID NO: 31.

[0068] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 and has at least 95% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 31 and has at least 95% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 95% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31 and has at least 95% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 31.

[0069] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 24 and has at least 95% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 31 and has at least 95% sequence identity to the at least 470 consecutive amino acid residues of SEQ ID NO: 31.

[0070] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 and has at least 99% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 31 and has at least 99% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 99% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31 and has at least 99% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 31. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 24 and has at least 99% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 31 and has at least 99% sequence identity to the at least 470 consecutive amino acid residues of SEQ ID NO: 31.

[0071] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 31.

[0072] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain

variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence that has at least 90% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 90% sequence identity to the amino acid sequence according to SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence that has at least 95% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 95% sequence identity to the amino acid sequence according to SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence that has at least 96% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 96% sequence identity to the amino acid sequence according to SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence that has at least 97% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 97% sequence identity to the amino acid sequence according to SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 32.

[0073] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of

the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 32.

[0074] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 32 and has at least 80% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 32 and has at least 80% sequence identity to the at least 470 consecutive amino acid residues of SEQ ID NO: 32.

[0075] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 and has at least 90% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of

the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 32 and has at least 90% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 90% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32 and has at least 90% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 24 and has at least 90% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 32 and has at least 90% sequence identity to the at least 470 consecutive amino acid residues of SEQ ID NO: 32.

[0076] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 and has at least 95% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 32 and has at least 95% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 95% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32 and has at least 95% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 32.

[0077] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 24 and has at least 95% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an

amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 32 and has at least 95% sequence identity to the at least 470 consecutive amino acid residues of SEQ ID NO: 32.

[0078] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 and has at least 99% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 32 and has at least 99% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 99% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32 and has at least 99% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 32. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 24 and has at least 99% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 32 and has at least 99% sequence identity to the at least 470 consecutive amino acid residues of SEQ ID NO: 32.

[0079] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 32.

[0080] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 90% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that

is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 90% sequence identity to the amino acid sequence according to SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 95% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 95% sequence identity to the amino acid sequence according to SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 96% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 96% sequence identity to the amino acid sequence according to SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 97% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 97% sequence identity to the amino acid sequence according to SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 33.

[0081] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid

residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 220 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 460 consecutive amino acid residues of SEQ ID NO: 33.

[0082] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 26 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 33 and has at least 80% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 220 consecutive amino acid residues of SEQ ID NO: 26 and has at least 80% sequence identity to the at least 220 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 460 consecutive amino acid residues of SEQ ID NO: 33 and has at least 80% sequence identity to the at least 460 consecutive amino acid residues of SEQ ID NO: 33.

[0083] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 26 and has at least 90% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 33 and has at least 90% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain

and the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26 and has at least 90% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33 and has at least 90% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 220 consecutive amino acid residues of SEQ ID NO: 26 and has at least 90% sequence identity to the at least 220 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 460 consecutive amino acid residues of SEQ ID NO: 33 and has at least 90% sequence identity to the at least 460 consecutive amino acid residues of SEQ ID NO: 33.

[0084] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 26 and has at least 95% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 33 and has at least 95% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26 and has at least 95% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33 and has at least 95% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 220 consecutive amino acid residues of SEQ ID NO: 26 and has at least 95% sequence identity to the at least 220 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 460 consecutive amino acid residues of SEQ ID NO: 33 and has at least 95% sequence identity to the at least 460 consecutive amino acid residues of SEQ ID NO: 33.

[0085] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 26 and has at least 99% sequence identity to the at

least 100 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 33 and has at least 99% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26 and has at least 99% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33 and has at least 99% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 33. In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence of at least 220 consecutive amino acid residues of SEQ ID NO: 26 and has at least 99% sequence identity to the at least 220 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 460 consecutive amino acid residues of SEQ ID NO: 33 and has at least 99% sequence identity to the at least 460 consecutive amino acid residues.

[0086] In some embodiments, the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 33.

[0087] In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 31, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 90% sequence identity to the amino acid sequence according to SEQ ID NO: 31, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 90% sequence identity to the amino acid sequence according to SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 95% sequence identity to the amino acid sequence according to SEQ ID NO: 31, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino

acid sequence that has at least 95% sequence identity to the amino acid sequence according to SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 96% sequence identity to the amino acid sequence according to SEQ ID NO: 31, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 96% sequence identity to the amino acid sequence according to SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 97% sequence identity to the amino acid sequence according to SEQ ID NO: 31, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 97% sequence identity to the amino acid sequence according to SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 31, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 98% sequence identity to the amino acid sequence according to SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 31, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 99% sequence identity to the amino acid sequence according to SEQ ID NO: 34.

[0088] In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 31, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 31, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 31, and an amino acid sequence of the Fab light chain polypeptide that is

connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 34.

[0089] In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 31 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 31 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 34 and has at least 80% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 31 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 31 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 31 and has at least 80% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 31 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 34 and has at least 80% sequence identity to the at least 470 consecutive amino acid residues of SEQ ID NO: 34.

[0090] In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 31 and has at least 90% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 31 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 34 and has at least 90% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 31 and has at least 90% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 31 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34 and has at least 90% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the

linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 31 and has at least 90% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 31 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 34 and has at least 90% sequence identity to the at least 470 consecutive amino acid residues of SEQ ID NO: 34.

[0091] In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 31 and has at least 95% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 31 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 34 and has at least 95% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 31 and has at least 95% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 31 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34 and has at least 95% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 34.

[0092] In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab heavy chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 31 and has at least 95% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 31 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 34 and has at least 95% sequence identity to the at least 470 consecutive amino acid residues of SEQ ID NO: 34.

[0093] In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 31 and has at least 99% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 31 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 34 and has at least 99% sequence identity to the at least 400 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino

acid residues of SEQ ID NO: 31 and has at least 99% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 31 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34 and has at least 99% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 34. In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab heavy chain polypeptide comprises an amino acid sequence of at least 210 consecutive amino acid residues of SEQ ID NO: 31 and has at least 99% sequence identity to the at least 210 consecutive amino acid residues of SEQ ID NO: 31 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 470 consecutive amino acid residues of SEQ ID NO: 34 and has at least 99% sequence identity to the at least 470 consecutive amino acid residues of SEQ ID NO: 34.

[0094] In some embodiments, the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 31, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 34.

Table 8. Antibody sequences that bind to EGFR and CD3

Construct Description	Amino Acid Sequence (N to C)	SEQ ID NO:
Ab-1 LC	QILLTQSPVILSVSPGERVSFSC RAS <u>QSIGTNI</u> HWYQQRTNGSP RLLIKY <u>ASE</u> SISGIPSRFSGSGS GTDFTLSINSVESEDIADYYCQ <u>QNNNWPTT</u> FGAGTKLELKRT VAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKST YLSSTLTLSKADYEKHKVYA CEVTHQGLSSPVTKSFNRGEC	24
Ab-1 HC	EVQLVESGGGLVQPGGSLKLS CAAS <u>GFTENKY</u> AMNWVRQA PGKGLEWVAR <u>IRSKYNNYAT</u> YYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYC <u>VRH</u> <u>GNFGNSYISYWAY</u> WGQGLV TVSSGGGGSGGGGSGGGGSQT VVTQEPSTLVSPGGTVTLTCS <u>STGAVTSGNY</u> PNWVQQKPGQ APRGLIG <u>GTK</u> FLAPGTPARFSG SLLGGKAALTLSGVQPEDEAE YYC <u>VLWYSNRWV</u> FGGGTKL TVLGGGGSQVQLKQSGPGLV QPSQSLSTCTVS <u>GFSLTNYGV</u> HWVRQSPGKGLEWLGVI <u>WSG</u> <u>GNTDYNTPFTSRLS</u> INKDNSKS	31

	QVFFKMNSLQSQDTAIYYCAR ALTYDYEFAYWGQGLVTV SAASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSW NSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICN VNHKPSNTKVDKKVEPKSC	
Ab-2 LC	QILLTQSPVILSVSPGERVSFSC RASQSIGTNIHWYQQRNGSP RLLIK Y ASESISGIPSRFSGSGS GTDFTLSINSVESEDIADYYCQ QNNNWPTTFGAGTKLELKRT VAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDST YLSSTLTLSKADYEKHKVYA CEVTHQGLSSPVTKSFNRGEC	24
Ab-2 HC	QTVVTQEPSLTVSPGGTVTLT CRSSTGAVTTSNYANWVQQK PGQAPRGLIGGTNKRAPGTPA RFSGSLLGGKAALTLSGVQPE DEAEYYCALWYSNLWVFGG GTKLTVLGGGSGGGGSGGG GSEVQLVESGGGLVQPGGSLK LSCAASGFTENTYAMNWVRQ APGKGLEWVARIRSKYNNYA TYYADSVKDRFTISRDDSKNT AYLQMNNLKTEDTAVYYCVR HGNFGNSYVSWFAYWGQGT LTVVSSGGGGSQVQLKQSGPG LVQPSQSLITCTVSGFSLTNY GVHWVRQSPGKGLEWLGVI WSGGNTDYNTPFTSRLSINKD NSKSQVFFKMNSLQSQDTAIY YCARALTYDYEFAYWGQ TLVTVSAASTKGPSVFPLAPSS KSTSGGTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEP KSC	32
Ab-3 LC	DILLTQSPVILSVSPGERVSFSC RASQSIGTNIHWYQQRNGSP RLLIK Y ASESISGIPSRFSGSGS GTDFTLSINSVESEDIADYYCQ QNNNWPTTFGAGTKLELKRT VAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPREAKVQWKVD NALQSGNSQESVTEQDSKDST YLSSTLTLSKADYEKHKVYA CEVTHQGLSSPVTKSFNRGEC	26
Ab-3 HC	QTVVTQEPSLTVSPGGTVTLT CRSSTGAVTTSNYANWVQQK PGQAPRGLIGGTNKRAPGTPA RFSGSLLGGKAALTLSGVQPE DEAEYYCALWYSNLWVFGG	33

	GTKLTVLGGGSGGGGSGGG GSEVQLVESGGGLVQPGGSLK LSCAAS<u>SGFTFNTY</u>AMNWVRQ APGKGLEWVAR<u>IRSKYNNYA</u> <u>TTY</u>ADSVKDRFTISRDDSKNT AYLQMNNLKTEDTAVYYC<u>VR</u> <u>HGNFGNSYVSWFAY</u>WGQGT LVTVSSGGGGSQVQLKQSGPG LVQPSQSLITCTVS<u>GFSLTNY</u> <u>GVHWVRQSPGKGLEWLGVI</u> <u>WGGNTDYNTPFTSRLSINKD</u> NSKSQVFFKMNSLQSNDAIY YC<u>ARALTYDYEFAY</u>WGQG TLVTVSAASTKGPSVFPLAPSS KSTSGGTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVTVPSSSLGTQ TYICNVNHKPSNTKVDKKVEP KSC	
Ab-4 HC	QVQLKQSGPGLVQPSQSLITC TVS<u>GFSLTNYGVHWVRQSPG</u> <u>KGLEWLGVIWGGNTDYNTP</u> FTSRLSINKDNSKSQVFFKMNS LQSQDTAIYYC<u>ARALTYDYE</u> <u>FA</u>YWGQGTTLVTVSAASTKG PSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSC	27
Ab-4 LC	EVQLVESGGGLVQPGGSLKLS CAAS<u>SGFTFNKY</u>AMNWVRQA PGKGLEWVAR<u>IRSKYNNYA</u>T YYADSVKDRFTISRDDSKNTA YLQMNNLKTEDTAVYYC<u>VRH</u> <u>GNFGNSYISYWAY</u>WGQGT TVSSGGGSGGGGSGGGGSQT VVTQEPSLTVSPGGTVTLTCGS <u>STGAVTSGNYPNWVQKPGQ</u> <u>APRGLIGGTK</u>FLAPGTPARFSG SLLGGKAALTLSGVQPEDEAE YYC<u>VLWYSNRWV</u>FGGGTKL TVLGGGGSQILLTQSPVILSVS PGERVSFSCRAS<u>OSIGTNIHW</u> YQQRNGSPRLLIK<u>YASE</u>SISGI PSRFSGSGGTDFTLINSVESE DIADYYC<u>QONNNWPTT</u>FGAG TKLELKRTVAAPSVFIFPPSDE QLKSGTASVVCLLNNFYPREA KVQWKVDNALQSGNSQESVT EQDSKDSTYSLSTLTLSKADY EKHKVYACEVTHQGLSSPVTK SFNRGEC	34

[0095] In some embodiments, the isolated polypeptide complex comprises a modified amino acid or non-natural amino acid, or a modified non-natural amino acid, or a combination thereof. In some embodiments, the modified amino acid or a modified non-natural amino acid comprises a post-translational modification. In some embodiments the isolated polypeptide complex comprises a modification including, but not limited to acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. Modifications are made anywhere to the isolated polypeptide complex including the peptide backbone, the amino acid side chains, and the terminus.

Polynucleotides Encoding Polypeptides or Polypeptide Complexes

[0096] Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding polypeptides or polypeptide complexes as disclosed herein. Described herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding polypeptides comprising an antibody that selectively binds to CD3 and EGFR.

[0097] Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding polypeptides of a polypeptide complex according to the following formula:

$$\text{A-L-B}$$

(Formula I)

wherein A comprises a single chain variable fragment (scFv) that binds to CD3; and B comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L comprises a linker that connects A to B. Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding polypeptides of a polypeptide complex comprising the following formula:

$$\text{A-L-B}$$

(Formula I)

wherein A comprises a single chain variable fragment (scFv) that binds to CD3; and B comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain

polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L comprises a linker that connects A to B. Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding polypeptides of a polypeptide complex comprising the following formula:

A-L-B

(Formula I)

wherein A is a single chain variable fragment (scFv) that binds to CD3; and B is an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L is a linker that connects A to B. Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding polypeptides of a polypeptide complex according to the following formula:

A-L-B

(Formula I)

wherein A is a single chain variable fragment (scFv) that binds to CD3; and B is an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L is a linker that connects A to B.

[0098] Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding polypeptides of a polypeptide complex according to the following formula:

A-L-D

(Formula II)

wherein A comprises a single chain variable fragment (scFv) that binds to CD3; D comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L comprises a linker that connects the C-terminus of A to an N-terminus of D. Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding polypeptides of a polypeptide complex comprising the following formula:

A-L-D

(Formula II)

wherein A comprises a single chain variable fragment (scFv) that binds to CD3; D comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L comprises a linker that connects the C-terminus of A to an N-terminus of D. Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding polypeptides of a polypeptide complex comprising the following formula:

A-L-D

(Formula II)

wherein A is a single chain variable fragment (scFv) that binds to CD3; D is an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L is a linker that connects the C-terminus of A to an N-terminus of D. Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding polypeptides of a polypeptide complex according to the following formula:

A-L-D

(Formula II)

wherein A is a single chain variable fragment (scFv) that binds to CD3; D is an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L is a linker that connects the C-terminus of A to an N-terminus of D. [0099] Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding an isolated polypeptide comprising an amino acid according to SEQ ID NO: 24.

[00100] Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding an isolated polypeptide comprising an amino acid according to SEQ ID NO: 25.

[00101] Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding an isolated polypeptide comprising an amino acid according to SEQ ID NO: 26.

[00102] Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding an isolated polypeptide comprising an amino acid according to SEQ ID NO: 27.

[00103] Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding an isolated polypeptide comprising an amino acid according to SEQ ID NO: 31.

[00104] Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding an isolated polypeptide comprising an amino acid according to SEQ ID NO: 32.

[00105] Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding an isolated polypeptide comprising an amino acid according to SEQ ID NO: 33.

[00106] Disclosed herein, in some embodiments, are isolated recombinant nucleic acid molecules encoding an isolated polypeptide comprising an amino acid according to SEQ ID NO: 34.

Pharmaceutical Compositions

[00107] Disclosed herein, in some embodiments, are pharmaceutical compositions comprising: (a) isolated the polypeptides or polypeptide complexes as disclosed herein; and (b) a pharmaceutically acceptable excipient.

[00108] In some embodiments, the pharmaceutical composition comprises (a) an isolated polypeptide complex according to Formula I:

A-L-B

(Formula I)

wherein A comprises a single chain variable fragment (scFv) that binds to CD3; and B comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L comprises a linker that connects A to B and (b) a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises (a) an isolated polypeptide complex comprising Formula I:

A-L-B

(Formula I)

wherein A comprises a single chain variable fragment (scFv) that binds to CD3; and B comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L comprises a linker that connects A to B and (b) a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises (a) an isolated polypeptide complex comprising Formula I:

A-L-B

(Formula I)

wherein A is a single chain variable fragment (scFv) that binds to CD3; and B is an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L is a linker that connects A to B and (b) a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises (a) an isolated polypeptide complex according to Formula I:

A-L-B

(Formula I)

wherein A is a single chain variable fragment (scFv) that binds to CD3; and B is an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L is a linker that connects A to B and (b) a pharmaceutically acceptable excipient.

[00109] In some embodiments, the pharmaceutical composition comprises (a) an isolated polypeptide complex according to Formula I:

A-L-D

(Formula II)

wherein A comprises a single chain variable fragment (scFv) that binds to CD3; D comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L comprises a linker that connects the C-terminus of A to an N-terminus of D and (b) a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises (a) an isolated polypeptide complex comprising Formula I:

A-L-D

(Formula II)

wherein A comprises a single chain variable fragment (scFv) that binds to CD3; D comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L comprises a linker that connects the C-terminus of A to an N-terminus of D and (b) a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises (a) an isolated polypeptide complex comprising Formula I:

A-L-D

(Formula II)

wherein A is a single chain variable fragment (scFv) that binds to CD3; D is an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L is a linker that connects the C-terminus of A to an N-terminus of D and (b) a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises (a) an isolated polypeptide complex according to Formula I:

A-L-D

(Formula II)

wherein A is a single chain variable fragment (scFv) that binds to CD3; D is an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L is a linker that connects the C-terminus of A to an N-terminus of D and (b) a pharmaceutically acceptable excipient.

[00110] In some embodiments, the polypeptide or polypeptide complex further comprises a detectable label, a therapeutic agent, or a pharmacokinetic modifying moiety. In some embodiments, the detectable label comprises a fluorescent label, a radiolabel, an enzyme, a nucleic acid probe, or a contrast agent.

[00111] For administration to a subject, the polypeptide or polypeptide complex as disclosed herein, may be provided in a pharmaceutical composition together with one or more pharmaceutically acceptable carriers or excipients. The term "pharmaceutically acceptable carrier" includes, but is not limited to, any carrier that does not interfere with the effectiveness of the biological activity of the ingredients and that is not toxic to the patient to whom it is administered. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Such carriers can be formulated by conventional methods and can be administered to the subject at a suitable dose. Preferably, the compositions are sterile. These compositions may also contain adjuvants such as preservative, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents.

[00112] The pharmaceutical composition may be in any suitable form, (depending upon the desired method of administration). It may be provided in unit dosage form, may be provided in a sealed container and may be provided as part of a kit. Such a kit may include instructions for use. It may include a plurality of said unit dosage forms.

[00113] The pharmaceutical composition may be adapted for administration by any appropriate route, including a parenteral (e.g., subcutaneous, intramuscular, or intravenous) route. Such compositions may be prepared by any method known in the art of pharmacy, for example by mixing the active ingredient with the carrier(s) or excipient(s) under sterile conditions.

[00114] Dosages of the substances of the present disclosure can vary between wide limits, depending upon the disease or disorder to be treated, the age and condition of the individual to be treated, etc. and a physician will ultimately determine appropriate dosages to be used.

Methods of Treatment

[0035] In some embodiments, the antibodies described herein are used in a method of treating cancer. In some embodiments, the cancer has cells that express EGFR. In some embodiments, the polypeptides or polypeptide complexes described herein are used in a method of treating colorectal cancer (CRC), squamous cell carcinoma of the head and Neck (SCCHN), non-small cell lung cancer (NSCLC), prostate cancer, breast cancer, colon/rectum cancer, head and neck cancer, esophagogastric cancer, liver cancer, glioblastoma, cervical cancer, ovarian cancer, bladder cancer, kidney cancer, or pancreatic cancer. In some embodiments, the polypeptides or polypeptide complexes described herein are used in a method of treating subjects who are resistant to EGFR inhibitor treatment. In some embodiments, the polypeptides or polypeptide complexes described herein are used in a method of treating subjects who harbor KRAS mutations. In some embodiments, the polypeptides or polypeptide complexes described herein are used in a method of treating subjects who are resistant to EGFR inhibitor treatment and harbor KRAS mutations.

Production of Antibodies that bind to EGFR and CD3

[00115] In some embodiments, polypeptides described herein (e.g., antibodies and its binding fragments) are produced using any method known in the art to be useful for the synthesis of polypeptides (e.g., antibodies), in particular, by chemical synthesis or by recombinant expression, and are preferably produced by recombinant expression techniques.

[00116] In some instances, an antibody or its binding fragment thereof is expressed recombinantly, and the nucleic acid encoding the antibody or its binding fragment is assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., 1994, BioTechniques 17:242), which involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligation of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

[00117] Alternatively, a nucleic acid molecule encoding an antibody is optionally generated from a suitable source (e.g., an antibody cDNA library, or cDNA library generated from any tissue or cells expressing the immunoglobulin) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence.

[00118] In some instances, an antibody or its binding is optionally generated by immunizing an animal, such as a mouse, to generate polyclonal antibodies or, more preferably, by generating monoclonal antibodies, e.g., as described by Kohler and Milstein (1975, Nature 256:495-497) or, as described by Kozbor et al. (1983, Immunology Today 4:72) or Cole et al. (1985 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Alternatively, a clone encoding at least the Fab portion of the antibody is optionally obtained by screening Fab expression libraries (e.g., as described in Huse et al., 1989, Science 246:1275-1281) for clones of Fab fragments that bind the specific antigen or by screening antibody libraries (See, e.g., Clackson et al., 1991, Nature 352:624; Hane et al., 1997 Proc. Natl. Acad. Sci. USA 94:4937).

[00119] In some embodiments, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci. 81:851-855; Neuberger et al., 1984, Nature 312:604-608; Takeda et al.,

1985, *Nature* 314:452-454) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity are used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region.

[00120] In some embodiments, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,694,778; Bird, 1988, *Science* 242:423-42; Huston et al., 1988, *Proc. Natl. Acad. Sci. USA* 85:5879-5883; and Ward et al., 1989, *Nature* 334:544-54) are adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in *E. coli* are also optionally used (Skerra et al., 1988, *Science* 242:1038-1041).

[00121] In some embodiments, an expression vector comprising the nucleotide sequence of an antibody or the nucleotide sequence of an antibody is transferred to a host cell by conventional techniques (e.g., electroporation, liposomal transfection, and calcium phosphate precipitation), and the transfected cells are then cultured by conventional techniques to produce the antibody. In specific embodiments, the expression of the antibody is regulated by a constitutive, an inducible or a tissue, specific promoter.

[00122] In some embodiments, a variety of host-expression vector systems is utilized to express an antibody, or its binding fragment described herein. Such host-expression systems represent vehicles by which the coding sequences of the antibody is produced and subsequently purified, but also represent cells that are, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody or its binding fragment in situ. These include, but are not limited to, microorganisms such as bacteria (e.g., *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing an antibody or its binding fragment coding sequences; yeast (e.g., *Saccharomyces Pichia*) transformed with recombinant yeast expression vectors containing an antibody or its binding fragment coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing an antibody or its binding fragment coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing an antibody or its binding fragment coding sequences; or mammalian cell systems (e.g., COS, CHO, BH, 293, 293T, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g. the adenovirus late promoter; the vaccinia virus 7.5K promoter).

[00123] For long-term, high-yield production of recombinant proteins, stable expression is preferred. In some instances, cell lines that stably express an antibody are optionally engineered. Rather than using expression vectors that contain viral origins of replication, host cells are transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells are then

allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci that in turn are cloned and expanded into cell lines. This method can advantageously be used to engineer cell lines which express the antibody or its binding fragments.

[00124] In some instances, a number of selection systems are used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1972, Proc. Natl. Acad. Sci. USA 48:202), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes are employed in tk⁻, hgp⁺ or ap⁺ cells, respectively. Also, antimetabolite resistance are used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Proc. Natl. Acad. Sci. USA 77:357; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Clinical Pharmacy 12:488-505; Wu and Wu, 1991, Biotherapy 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217; May 1993, TIB TECH 11(5):155-215) and hyg⁺, which confers resistance to hygromycin (Santerre et al., 1984, Gene 30:147). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds., 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY; and in Chapters 12 and 13, Dracopoli et al. (eds), 1994, Current Protocols in Human Genetics, John Wiley & Sons, NY.; Colberre-Garapin et al., 1981, J. Mol. Biol. 150:1).

[00125] In some instances, the expression levels of an antibody are increased by vector amplification (for a review, see Bebbington and Hentschel, the use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol. 3. (Academic Press, New York, 1987)). When a marker in the vector system expressing an antibody is amplifiable, an increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the nucleotide sequence of the antibody, production of the antibody will also increase (Crouse et al., 1983, Mol. Cell Biol. 3:257).

[00126] In some instances, any method known in the art for purification of an antibody is used, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.

Expression Vectors

[00127] In some embodiments, vectors include any suitable vectors derived from either a eukaryotic or prokaryotic sources. In some cases, vectors are obtained from bacteria (e.g. E. coli), insects, yeast (e.g. Pichia pastoris), algae, or mammalian sources. Exemplary bacterial vectors include pACYC177, pASK75, pBAD vector series, pBADM vector series, pET vector series, pETM vector series, pGEX vector series, pHAT,

pHAT2, pMal-c2, pMal-p2, pQE vector series, pRSET A, pRSET B, pRSET C, pTrcHis2 series, pZA31-Luc, pZE21-MCS-1, pFLAG ATS, pFLAG CTS, pFLAG MAC, pFLAG Shift-12c, pTAC-MAT-1, pFLAG CTC, or pTAC-MAT-2.

[00128] Exemplary insect vectors include pFastBac1, pFastBac DUAL, pFastBac ET, pFastBac HTa, pFastBac HTb, pFastBac HTc, pFastBac M30a, pFastBac M30b, pFastBac M30c, pVL1392, pVL1393, pVL1393 M10, pVL1393 M11, pVL1393 M12, FLAG vectors such as pPolh-FLAG1 or pPolh-MAT 2, or MAT vectors such as pPolh-MAT1, or pPolh-MAT2.

[00129] In some cases, yeast vectors include Gateway® pDEST™ 14 vector, Gateway® pDEST™ 15 vector, Gateway® pDEST™ 17 vector, Gateway® pDEST™ 24 vector, Gateway® pYES-DEST52 vector, pBAD-DEST49 Gateway® destination vector, pAO815 Pichia vector, pFLD1 Pichi pastoris vector, pGAPZA,B, & C Pichia pastoris vector, pPIC3.5K Pichia vector, pPIC6 A, B, & C Pichia vector, pPIC9K Pichia vector, pTEF1/Zeo, pYES2 yeast vector, pYES2/CT yeast vector, pYES2/NT A, B, & C yeast vector, or pYES3/CT yeast vector.

[00130] Exemplary algae vectors include pChlamy-4 vector or MCS vector.

[00131] Examples of mammalian vectors include transient expression vectors or stable expression vectors. Mammalian transient expression vectors may include pRK5, p3xFLAG-CMV 8, pFLAG-Myc-CMV 19, pFLAG-Myc-CMV 23, pFLAG-CMV 2, pFLAG-CMV 6a,b,c, pFLAG-CMV 5.1, pFLAG-CMV 5a,b,c, p3xFLAG-CMV 7.1, pFLAG-CMV 20, p3xFLAG-Myc-CMV 24, pCMV-FLAG-MAT1, pCMV-FLAG-MAT2, pBICEP-CMV 3, or pBICEP-CMV 4. Mammalian stable expression vector may include pFLAG-CMV 3, p3xFLAG-CMV 9, p3xFLAG-CMV 13, pFLAG-Myc-CMV 21, p3xFLAG-Myc-CMV 25, pFLAG-CMV 4, p3xFLAG-CMV 10, p3xFLAG-CMV 14, pFLAG-Myc-CMV 22, p3xFLAG-Myc-CMV 26, pBICEP-CMV 1, or pBICEP-CMV 2.

[00132] In some instances, a cell-free system is a mixture of cytoplasmic and/or nuclear components from a cell and is used for in vitro nucleic acid synthesis. In some cases, a cell-free system utilizes either prokaryotic cell components or eukaryotic cell components. Sometimes, a nucleic acid synthesis is obtained in a cell-free system based on for example Drosophila cell, Xenopus egg, or HeLa cells. Exemplary cell-free systems include, but are not limited to, E. coli S30 Extract system, E. coli T7 S30 system, or PURExpress®.

Host Cells

[00133] In some embodiments, a host cell includes any suitable cell such as a naturally derived cell or a genetically modified cell. In some instances, a host cell is a production host cell. In some instances, a host cell is a eukaryotic cell. In other instances, a host cell is a prokaryotic cell. In some cases, a eukaryotic cell includes fungi (e.g., yeast cells), animal cell or plant cell. In some cases, a prokaryotic cell is a bacterial cell. Examples of bacterial cell include gram-positive bacteria or gram-negative bacteria. Sometimes the gram-negative bacteria is anaerobic, rod-shaped, or both.

[00134] In some instances, gram-positive bacteria include Actinobacteria, Firmicutes or Tenericutes. In some cases, gram-negative bacteria include Aquificae, Deinococcus-Thermus, Fibrobacteres-Chlorobi/Bacteroidetes (FCB group), Fusobacteria, Gemmatimonadetes, Nitrospirae, Planctomycetes-

Verrucomicrobia/ Chlamydiae (PVC group), Proteobacteria, Spirochaetes or Synergistetes. Other bacteria can be Acidobacteria, Chloroflexi, Chrysiogenetes, Cyanobacteria, Deferribacteres, Dictyoglomi, Thermodesulfobacteria or Thermotogae. A bacterial cell can be *Escherichia coli*, *Clostridium botulinum*, or *Coli bacilli*.

[00135] Exemplary prokaryotic host cells include, but are not limited to, BL21, Mach1™, DH10B™, TOP10, DH5α, DH10Bac™, OmniMax™, MegaX™, DH12S™, INV110, TOP10F', INVαF, TOP10/P3, ccdB Survival, PIR1, PIR2, Stbl2™, Stbl3™, or Stbl4™.

[00136] In some instances, animal cells include a cell from a vertebrate or from an invertebrate. In some cases, an animal cell includes a cell from a marine invertebrate, fish, insects, amphibian, reptile, or mammal. In some cases, a fungus cell includes a yeast cell, such as brewer's yeast, baker's yeast, or wine yeast.

[00137] Fungi include ascomycetes such as yeast, mold, filamentous fungi, basidiomycetes, or zygomycetes. In some instances, yeast includes Ascomycota or Basidiomycota. In some cases, Ascomycota includes Saccharomycotina (true yeasts, e.g. *Saccharomyces cerevisiae* (baker's yeast)) or Taphrinomycotina (e.g. Schizosaccharomycetes (fission yeasts)). In some cases, Basidiomycota includes Agaricomycotina (e.g. Tremellomycetes) or Pucciniomycotina (e.g. Microbotryomycetes).

[00138] Exemplary yeast or filamentous fungi include, for example, the genus: *Saccharomyces*, *Schizosaccharomyces*, *Candida*, *Pichia*, *Hansenula*, *Kluyveromyces*, *Zygosaccharomyces*, *Yarrowia*, *Trichosporon*, *Rhodospiridi*, *Aspergillus*, *Fusarium*, or *Trichoderma*. Exemplary yeast or filamentous fungi include, for example, the species: *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Candida utilis*, *Candida boidini*, *Candida albicans*, *Candida tropicalis*, *Candida stellatoidea*, *Candida glabrata*, *Candida krusei*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida viswanathii*, *Candida lusitaniae*, *Rhodotorula mucilaginosa*, *Pichia metanolica*, *Pichia angusta*, *Pichia pastoris*, *Pichia anomala*, *Hansenula polymorpha*, *Kluyveromyces lactis*, *Zygosaccharomyces rouxii*, *Yarrowia lipolytica*, *Trichosporon pullulans*, *Rhodospiridium toru-Aspergillus niger*, *Aspergillus nidulans*, *Aspergillus awamori*, *Aspergillus oryzae*, *Trichoderma reesei*, *Yarrowia lipolytica*, *Brettanomyces bruxellensis*, *Candida stellata*, *Schizosaccharomyces pombe*, *Torulaspora delbrueckii*, *Zygosaccharomyces bailii*, *Cryptococcus neoformans*, *Cryptococcus gattii*, or *Saccharomyces boulardii*.

[00139] Exemplary yeast host cells include, but are not limited to, *Pichia pastoris* yeast strains such as GS115, KM71H, SMD1168, SMD1168H, and X-33; and *Saccharomyces cerevisiae* yeast strain such as INVSc1.

[00140] In some instances, additional animal cells include cells obtained from a mollusk, arthropod, annelid or sponge. In some cases, an additional animal cell is a mammalian cell, e.g., from a primate, ape, equine, bovine, porcine, canine, feline or rodent. In some cases, a rodent includes mouse, rat, hamster, gerbil, hamster, chinchilla, fancy rat, or guinea pig.

[00141] Exemplary mammalian host cells include, but are not limited to, 293A cell line, 293FT cell line, 293F cells, 293 H cells, CHO DG44 cells, CHO-S cells, CHO-K1 cells, FUT8 KO CHOK1, Expi293F™ cells, Flp-In™ T-REx™ 293 cell line, Flp-In™-293 cell line, Flp-In™-3T3 cell line, Flp-In™-BHK cell line, Flp-In™-CHO cell line, Flp-In™-CV-1 cell line, Flp-In™-Jurkat cell line, FreeStyle™ 293-F cells, FreeStyle™ CHO-

S cells, GripTite™ 293 MSR cell line, GS-CHO cell line, HepaRG™ cells, T-REx™ Jurkat cell line, Per.C6 cells, T-REx™-293 cell line, T-REx™-CHO cell line, and T-REx™-HeLa cell line.

[00142] In some instances, a mammalian host cell is a stable cell line, or a cell line that has incorporated a genetic material of interest into its own genome and has the capability to express the product of the genetic material after many generations of cell division. In some cases, a mammalian host cell is a transient cell line, or a cell line that has not incorporated a genetic material of interest into its own genome and does not have the capability to express the product of the genetic material after many generations of cell division.

[00143] Exemplary insect host cells include, but are not limited to, *Drosophila* S2 cells, Sf9 cells, Sf21 cells, High Five™ cells, and expresSF+® cells.

[00144] In some instances, plant cells include a cell from algae. Exemplary insect cell lines include, but are not limited to, strains from *Chlamydomonas reinhardtii* 137c, or *Synechococcus elongatus* PPC 7942.

Articles of Manufacture

[00145] In another aspect of the invention, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper that is pierceable by a hypodermic injection needle). At least one active agent in the composition is a bispecific antibody comprising a first antigen-binding site that specifically binds to CD3 and a second antigen-binding site that specifically binds to EGFR as defined herein before.

[00146] The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises the bispecific antibody of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.

[00147] Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

EMBODIMENTS

[00148] Embodiment 1 comprises an isolated polypeptide complex according to the following formula: A-L-B (Formula I) wherein A comprises a single chain variable fragment (scFv) that binds to CD3; B comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light

chain polypeptide comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and L comprises a linker that connects A to B.

[00149] Embodiment 2 comprises an isolated polypeptide complex of embodiment 1, wherein the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21, LC-CDR2: SEQ ID NO: 22, and LC-CDR3: SEQ ID NO: 23, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

[00150] Embodiment 3 comprises an isolated polypeptide complex according to embodiment 1 or 2, wherein the scFv comprises a scFv light chain variable domain and a scFv heavy chain variable domain.

[00151] Embodiment 4 comprises an isolated polypeptide complex according to embodiment 3, wherein the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise either HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 3; or HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3.

[00152] Embodiment 5 comprises an isolated polypeptide complex according to embodiment 3 or 4, wherein the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise either LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8; or LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11 and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

[00153] Embodiment 6 comprises an isolated polypeptide complex of any one of embodiments 1-5, wherein the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27.

[00154] Embodiment 7 comprises an isolated polypeptide complex of any one of embodiments 1-5, wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 25 or 27.

[00155] Embodiment 8 comprises an isolated polypeptide complex according to embodiment 7, wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27.

[00156] Embodiment 9 comprises an isolated polypeptide complex according to embodiment 7, wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27.

[00157] Embodiment 10 comprises an isolated polypeptide complex of any one of embodiments 1-9, wherein the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 25 or 27.

[00158] Embodiment 11 comprises an isolated polypeptide complex of any one of embodiments 1-10, wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24 or 26.

[00159] Embodiment 12 comprises an isolated polypeptide complex of any one of embodiments 1-10, wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 or 26.

[00160] Embodiment 13 comprises an isolated polypeptide complex according to embodiment 12, wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26.

[00161] Embodiment 14 comprises an isolated polypeptide complex according to embodiment 12, wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26.

[00162] Embodiment 15 comprises an isolated polypeptide complex of any one of embodiments 1-14, wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24 or 26.

[00163] Embodiment 16 comprises an isolated polypeptide complex of any one of embodiments 3-15, wherein the scFv heavy chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 13 or 16.

[00164] Embodiment 17 comprises an isolated polypeptide complex of any one of embodiments 3-16, wherein the scFv heavy chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 13 or 16.

[00165] Embodiment 18 comprises an isolated polypeptide complex of any one of embodiments 3-17, wherein the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16.

[00166] Embodiment 19 comprises an isolated polypeptide complex of any one of embodiments 3-18, wherein the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16.

[00167] Embodiment 20 comprises an isolated polypeptide complex of any one of embodiments 3-19, wherein the scFv heavy chain variable domain comprises an amino acid sequence according to SEQ ID NO: 13 or 16.

[00168] Embodiment 21 comprises an isolated polypeptide complex of any one of embodiments 3-20, wherein the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 12 or 15.

[00169] Embodiment 22 comprises an isolated polypeptide complex of any one of embodiments 3-20, wherein the scFv light chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 12 or 15.

[00170] Embodiment 23 comprises an isolated polypeptide complex according to embodiment 22, wherein the scFv light chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15.

[00171] Embodiment 24 comprises an isolated polypeptide complex according to embodiment 22, wherein the scFv light chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15.

[00172] Embodiment 25 comprises an isolated polypeptide complex of any one of embodiments 3-24, wherein the scFv light chain variable domain comprises an amino acid sequence according to SEQ ID NO: 12 or 15.

[00173] Embodiment 26 comprises an isolated polypeptide complex of any one of embodiments 1-25, wherein the scFv comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17.

[00174] Embodiment 27 comprises an isolated polypeptide complex of any one of embodiments 1-25, wherein the scFv comprises an amino acid sequence of at least 150 consecutive amino acid residues of SEQ ID NO: 14 or 17.

[00175] Embodiment 28 comprises an isolated polypeptide complex according to embodiment 27, wherein the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17.

[00176] Embodiment 29 comprises an isolated polypeptide complex according to embodiment 27, wherein the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17 and has at least 80% sequence identity to the at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17.

[00177] Embodiment 30 comprises an isolated polypeptide complex of any one of embodiments 1-29, wherein the scFv comprises an amino acid sequence according to SEQ ID NO: 14 or 17.

[00178] Embodiment 31 comprises an isolated polypeptide complex of any one of embodiments 1-30, wherein the linker connects the C-terminus of A to an N-terminus of B.

[00179] Embodiment 32 comprises an isolated polypeptide complex of any one of embodiments 1-30, wherein the linker connects the N-terminus of A to a C-terminus of B.

[00180] Embodiment 33 comprises an isolated polypeptide complex according to embodiment 31, wherein the linker connects the C-terminus of A to the N-terminus of the Fab heavy chain polypeptide.

[00181] Embodiment 34 comprises an isolated polypeptide complex according to embodiment 32, wherein the linker connects the N-terminus of A to the C-terminus of the Fab heavy chain polypeptide.

[00182] Embodiment 35 comprises an isolated polypeptide complex according to embodiment 31, wherein the linker connects the C-terminus of A to the N-terminus of the Fab light chain polypeptide.

[00183] Embodiment 36 comprises an isolated polypeptide complex according to embodiment 32, wherein the linker connects the N-terminus of A to the C-terminus of the Fab light chain polypeptide.

[00184] Embodiment 37 comprises an isolated polypeptide complex of any one of embodiments 3-32, wherein the linker connects the Fab light chain polypeptide to the scFv light chain variable domain.

[00185] Embodiment 38 comprises an isolated polypeptide complex of any one of embodiments 3-32, wherein the linker connects the Fab light chain polypeptide to the scFv heavy chain variable domain.

[00186] Embodiment 39 comprises an isolated polypeptide complex of any one of embodiments 3-32, wherein the linker connects the Fab heavy chain polypeptide to the scFv light chain variable domain.

[00187] Embodiment 40 comprises an isolated polypeptide complex of any one of embodiments 3-32, wherein the linker connects the Fab heavy chain polypeptide to the scFv heavy chain variable domain.

[00188] Embodiment 41 comprises an isolated polypeptide complex according to embodiment 36, wherein the linker connects the Fab light chain polypeptide to the N-terminus of the scFv light chain variable domain.

[00189] Embodiment 42 comprises an isolated polypeptide complex according to embodiment 35, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain.

[00190] Embodiment 43 comprises an isolated polypeptide complex according to embodiment 36, wherein the linker connects the Fab light chain polypeptide to the N-terminus of the scFv heavy chain variable domain.

[00191] Embodiment 44 comprises an isolated polypeptide complex according to embodiment 35, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv heavy chain variable domain.

[00192] Embodiment 45 comprises an isolated polypeptide complex according to embodiment 34, wherein the linker connects the Fab heavy chain polypeptide to the N-terminus of the scFv light chain variable domain.

[00193] Embodiment 46 comprises an isolated polypeptide complex according to embodiment 33, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain.

[00194] Embodiment 47 comprises an isolated polypeptide complex according to embodiment 34, wherein the linker connects the Fab heavy chain polypeptide to the N-terminus of the scFv heavy chain variable domain.

[00195] Embodiment 48 comprises an isolated polypeptide complex according to embodiment 33, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv heavy chain variable domain.

[00196] Embodiment 49 comprises an isolated polypeptide complex of any one of embodiments 1-48, wherein the linker is at least 5 amino acids in length.

[00197] Embodiment 50 comprises an isolated polypeptide complex of any one of embodiments 1-49, wherein the linker is no more than 30 amino acids in length.

[00198] Embodiment 51 comprises an isolated polypeptide complex of any one of embodiments 1-50, wherein the linker is at least 5 amino acids and no more than 30 amino acids in length.

[00199] Embodiment 52 comprises an isolated polypeptide complex of any one of embodiments 1-51, wherein the linker is 5 amino acids in length.

[00200] Embodiment 53 comprises an isolated polypeptide complex of any one of embodiments 1-51, wherein the linker is 15 amino acids in length.

[00201] Embodiment 54 comprises an isolated polypeptide complex of any one of embodiments 1-51, wherein the linker comprises an amino acid sequence of SEQ ID NO: 28 (GGGSGGGSGGGGS), SEQ ID NO: 29 (GGGGS), or SEQ ID NO: 30 (GGGSGGGGS).

[00202] Embodiment 55 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 31.

[00203] Embodiment 56 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 31.

[00204] Embodiment 57 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31.

[00205] Embodiment 58 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 31.

[00206] Embodiment 59 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 31.

[00207] Embodiment 60 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 32.

[00208] Embodiment 61 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 32.

[00209] Embodiment 62 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32.

[00210] Embodiment 63 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 32.

[00211] Embodiment 64 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 32.

[00212] Embodiment 65 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 33.

[00213] Embodiment 66 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 33.

[00214] Embodiment 67 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33.

[00215] Embodiment 68 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 33.

[00216] Embodiment 69 comprises an isolated polypeptide complex according to embodiment 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 33.

[00217] Embodiment 70 comprises an isolated polypeptide complex according to embodiment 42, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an

amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 34.

[00218] Embodiment 71 comprises an isolated polypeptide complex according to embodiment 42, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 34.

[00219] Embodiment 72 comprises an isolated polypeptide complex according to embodiment 42, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34.

[00220] Embodiment 73 comprises an isolated polypeptide complex according to embodiment 42, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 27 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 27 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 34.

[00221] Embodiment 74 comprises an isolated polypeptide complex according to embodiment 42, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 34.

[00222] Embodiment 75 comprises an isolated polypeptide complex according to the following formula: A-L-D (Formula II) wherein A comprises a single chain variable fragment (scFv) that binds to CD3; D comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR; and L comprises a linker that connects the C-terminus of A to an N-terminus of D.

[00223] Embodiment 76 comprises an isolated polypeptide complex according to embodiment 75, wherein the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain.

[00224] Embodiment 77 comprises an isolated polypeptide complex according to embodiment 75 or 76, wherein the scFv comprises a scFv light chain variable domain and a scFv heavy chain variable domain.

[00225] Embodiment 78 comprises an isolated polypeptide complex of any one of embodiments 76-77, wherein the linker connects the C-terminus of A to the N-terminus of the Fab heavy chain polypeptide.

[00226] Embodiment 79 comprises an isolated polypeptide complex of any one of embodiments 76-77, wherein the linker connects the C-terminus of A to the N-terminus of the Fab light chain polypeptide.

[00227] Embodiment 80 comprises an isolated polypeptide complex according to embodiment 78, wherein the linker connects the C-terminus of the scFv light chain variable domain to the N-terminus of the Fab heavy chain polypeptide.

[00228] Embodiment 81 comprises an isolated polypeptide complex according to embodiment 79, wherein the linker connects the C-terminus of scFv light chain variable domain to the N-terminus of the Fab light chain polypeptide.

[00229] Embodiment 82 comprises an isolated polypeptide complex according to embodiment 78, wherein the linker connects the C-terminus of the scFv heavy chain variable domain to the N-terminus of the Fab heavy chain polypeptide.

[00230] Embodiment 83 comprises an isolated polypeptide complex according to embodiment 79, wherein the linker connects the C-terminus of scFv heavy chain variable domain to the N-terminus of the Fab light chain polypeptide.

[00231] Embodiment 84 comprises an isolated polypeptide complex of any one of embodiments 76-83, wherein the Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3.

[00232] Embodiment 85 comprises an isolated polypeptide complex of any one of embodiments 76-83, wherein the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21; LC-CDR2: SEQ ID NO: 22; and LC-CDR3: SEQ ID NO: 23, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

[00233] Embodiment 86 comprises an isolated polypeptide complex of any one of embodiments 77-83, wherein the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: either HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, HC- and CDR3: SEQ ID NO: 3; or HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3.

[00234] Embodiment 87 comprises an isolated polypeptide complex of any one of embodiments 77-83, wherein the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-

CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise either LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8; or LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

[00235] Embodiment 88 comprises an isolated polypeptide complex of any one of embodiments 76-87, wherein the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27.

[00236] Embodiment 89 comprises an isolated polypeptide complex of any one of embodiments 76-87, wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 25 or 27.

[00237] Embodiment 90 comprises an isolated polypeptide complex according to embodiment 89, wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27.

[00238] Embodiment 91 comprises an isolated polypeptide complex according to embodiment 89, wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27.

[00239] Embodiment 92 comprises an isolated polypeptide complex of any one of embodiments 76-91, wherein the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 25 or 27.

[00240] Embodiment 93 comprises an isolated polypeptide complex of any one of embodiments 76-92, wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24 or 26.

[00241] Embodiment 94 comprises an isolated polypeptide complex of any one of embodiments 76-92, wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 or 26.

[00242] Embodiment 95 comprises an isolated polypeptide complex according to embodiment 94, wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26.

[00243] Embodiment 96 comprises an isolated polypeptide complex according to embodiment 94, wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26.

[00244] Embodiment 97 comprises an isolated polypeptide complex of any one of embodiments 76-96, wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24 or 26.

[00245] Embodiment 98 comprises an isolated polypeptide complex of any one of embodiments 77-97, wherein the scFv heavy chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 13 or 16.

[00246] Embodiment 99 comprises an isolated polypeptide complex of any one of embodiments 77-97, wherein the scFv heavy chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 13 or 16.

[00247] Embodiment 100 comprises an isolated polypeptide complex according to embodiment 99, wherein the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16.

[00248] Embodiment 101 comprises an isolated polypeptide complex according to embodiment 99, wherein the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16.

[00249] Embodiment 102 comprises an isolated polypeptide complex of any one of embodiments 77-101, wherein the scFv heavy chain variable domain comprises an amino acid sequence according to SEQ ID NO: 13 or 16.

[00250] Embodiment 103 comprises an isolated polypeptide complex of any one of embodiments 77-102, wherein the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 12 or 15.

[00251] Embodiment 104 comprises an isolated polypeptide complex of any one of embodiments 77-103, wherein the scFv light chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 12 or 15.

[00252] Embodiment 105 comprises an isolated polypeptide complex according to embodiment 104, wherein the scFv light chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15.

[00253] Embodiment 106 comprises an isolated polypeptide complex according to embodiment 104, wherein the scFv light chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15.

[00254] Embodiment 107 comprises an isolated polypeptide complex of any one of embodiments 77-106, wherein the scFv light chain variable domain comprises an amino acid sequence according to SEQ ID NO: 12 or 15.

[00255] Embodiment 108 comprises an isolated polypeptide complex of any one of embodiments 75-107, wherein the scFv comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17.

[00256] Embodiment 109 comprises an isolated polypeptide complex of any one of embodiments 75-107, wherein the scFv comprises an amino acid sequence of at least 150 consecutive amino acid residues of SEQ ID NO: 14 or 17.

[00257] Embodiment 110 comprises an isolated polypeptide complex according to embodiment 109, wherein the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17.

[00258] Embodiment 111 comprises an isolated polypeptide complex according to embodiment 109, wherein the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17 and has at least 80% sequence identity to the at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17.

[00259] Embodiment 112 comprises an isolated polypeptide complex of any one of embodiments 75-112, wherein the scFv comprises an amino acid sequence according to SEQ ID NO: 14 or 17.

[00260] Embodiment 113 comprises an isolated polypeptide complex of any one of embodiments 75-112, wherein the linker is at least 5 amino acids in length.

[00261] Embodiment 114 comprises an isolated polypeptide complex according to embodiment 113, wherein the linker is no more than 30 amino acids in length.

[00262] Embodiment 115 comprises an isolated polypeptide complex according to embodiment 114, wherein the linker is at least 5 amino acids and no more than 30 amino acids in length.

[00263] Embodiment 116 comprises an isolated polypeptide complex according to embodiment 115, wherein the linker is 5 amino acids in length.

[00264] Embodiment 117 comprises an isolated polypeptide complex according to embodiment 115, wherein the linker is 15 amino acids in length.

[00265] Embodiment 118 comprises an isolated polypeptide complex according to embodiment 115, wherein the linker comprises an amino acid sequence of SEQ ID NO: 28 (GGGSGGGSGGGGS), SEQ ID NO: 29 (GGGS), or SEQ ID NO: 30 (GGGSGGGGS).

[00266] Embodiment 119 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 31.

[00267] Embodiment 120 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that

is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 31.

[00268] Embodiment 121 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31.

[00269] Embodiment 122 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 31.

[00270] Embodiment 123 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 31.

[00271] Embodiment 124 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 32.

[00272] Embodiment 125 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 32.

[00273] Embodiment 126 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive

amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32.

[00274] Embodiment 127 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 32.

[00275] Embodiment 128 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 32.

[00276] Embodiment 129 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 33.

[00277] Embodiment 130 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 33.

[00278] Embodiment 131 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33.

[00279] Embodiment 132 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv heavy chain variable domain

and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 33.

[00280] Embodiment 133 comprises an isolated polypeptide complex according to embodiment 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 33.

[00281] Embodiment 134 comprises an isolated polypeptide complex according to embodiment 81, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 34.

[00282] Embodiment 135 comprises an isolated polypeptide complex according to embodiment 81, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 34.

[00283] Embodiment 136 comprises an isolated polypeptide complex according to embodiment 81, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34.

[00284] Embodiment 137 comprises an isolated polypeptide complex according to embodiment 81, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 27 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 27 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at

least 450 consecutive amino acid residues of SEQ ID NO: 34 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 34.

[00285] Embodiment 138 comprises an isolated polypeptide complex according to embodiment 81, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 34.

[00286] Embodiment 139 comprises an isolated polypeptide complex according to embodiment 77, wherein the Fab heavy chain variable domain comprises complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, HC-CDR3: SEQ ID NO: 20; the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21; LC-CDR2: SEQ ID NO: 22; and LC-CDR3: SEQ ID NO: 23; the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: either HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, HC-CDR3: SEQ ID NO: 3; or HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5; the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise either LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8; or LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11.

[00287] Embodiment 140 comprises an isolated polypeptide complex according to embodiment 77, wherein the Fab heavy chain variable domain comprises complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, HC-CDR3: SEQ ID NO: 20; the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21; LC-CDR2: SEQ ID NO: 22; and LC-CDR3: SEQ ID NO: 23; the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, HC-CDR3: SEQ ID NO: 3; the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8.

[00288] Embodiment 141 comprises an isolated polypeptide complex according to embodiment 77, wherein the Fab heavy chain variable domain comprises complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, HC-CDR3: SEQ ID NO: 20; the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21; LC-CDR2: SEQ ID NO: 22; and LC-CDR3: SEQ ID NO: 23; the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5; the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11.

[00289] Embodiment 142 comprises a pharmaceutical composition comprising: the isolated polypeptide complex of any one of embodiments 1-141; and a pharmaceutically acceptable excipient.

[00290] Embodiment 143 comprises an isolated recombinant nucleic acid molecule encoding a polypeptide of the polypeptide complex of any one of embodiments 1-141.

[00291] Embodiment 144 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating cancer.

[00292] Embodiment 145 comprises the isolated polypeptide complex of embodiment 144, wherein the cancer has cells that express EGFR.

[00293] Embodiment 146 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating colorectal cancer (CRC).

[00294] Embodiment 147 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating squamous cell carcinoma of the head and Neck (SCCHN).

[00295] Embodiment 148 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating non-small cell lung cancer (NSCLC).

[00296] Embodiment 149 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating prostate cancer.

[00297] Embodiment 150 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating breast cancer.

[00298] Embodiment 151 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating colon/rectum cancer.

[00299] Embodiment 152 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating head and neck cancer.

[00300] Embodiment 153 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating esophagogastric cancer.

[00301] Embodiment 154 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating liver cancer.

[00302] Embodiment 155 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating cervical cancer.

[00303] Embodiment 156 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating ovarian cancer.

[00304] Embodiment 157 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating bladder cancer.

[00305] Embodiment 158 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating kidney cancer.

[00306] Embodiment 159 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating pancreatic cancer.

[00307] Embodiment 160 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating subjects who are resistant to EGFR inhibitor treatment.

[00308] Embodiment 161 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating subjects who harbor KRAS mutations.

[00309] Embodiment 162 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating subjects who are resistant to EGFR inhibitor treatment and harbor KRAS mutations.

[00310] Embodiment 163 comprises an isolated polypeptide complex of any one of embodiments 1-141, for use in a method of treating glioblastoma.

EXAMPLES

Example 1: EGFR Polypeptide Complex Binding

[00311] The EGFR polypeptide complexes Ab-1, Ab-2, and Ab-3 were evaluated for EGFR and CD3e binding.

[00312] Ab-1, Ab-2, and Ab-3 comprise the sequences as listed in Table 9.

Table 9. Ab-1, Ab-3, and Ab-3 Sequences

Antibody sequences that bind to EGFR and CD3		
Ab-1 LC	QILLTQSPVILSVSPGERVSFSCRASQSIGTNIH WYQQRNTGSPRLLIK Y ASESISGIPSRFSGSGSG TDFTLINSVESEDIADYYCQONNNWPTTFGA GTKLELKRTVAAPSVFIFPPSDEQLKSGTASVV CLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSTLTLSKADYEKHKVYACEVT HQGLSSPVTKSFNRGEC	24
Ab-1 HC	EVQLVESGGGLVQPGGSLKLSCAASGFTFNKY AMNWVRQAPGKGLEWVARIRSKYNNYATYY ADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLLTVSS GGGGSGGGSGGGGSQTVVTQEPSTLVSPGGT VTLTCSSTGAVTSGNYPNWVQKPGQAPRG LIGGTKFLAPGTPARFSGSLLGGKAALTLGVQ PEDEAEYYCVLWYSNRWVFGGGTKLTVLGGG GSQVQLKQSGPGLVQPSQSLSTCTVSGFSLTN YGVHWVRQSPGKGLEWLGVIWSSGGNTDYN PFTSRLSINKDNSKSQVFFKMNSLQSQDTAIYY CARALTYDYEFAYWGQGTLLTVSAASTKGP SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT SWNSGALTSGVHTFPAVLQSSGLYSLSSVTV SSSLGTQTYICNVNHKPSNTKVDKKVEPKSC	31
Ab-2 LC	QILLTQSPVILSVSPGERVSFSCRASQSIGTNIH WYQQRNTGSPRLLIK Y ASESISGIPSRFSGSGSG TDFTLINSVESEDIADYYCQONNNWPTTFGA GTKLELKRTVAAPSVFIFPPSDEQLKSGTASVV CLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSTLTLSKADYEKHKVYACEVT HQGLSSPVTKSFNRGEC	24
Ab-2 HC	QTVVTQEPSTLVSPGGTTLTCSRSTGAVTTSN YANWVQKPGQAPRGLIGGTNKRAPGTPARFS GSLGGKAALTLGVQPEDEAEYYCALWYSN LWVFGGGTKLTVLGGGGSGGGSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNNTYAMN WVRQAPGKGLEWVARIRSKYNNYATYYADS VKDRFTISRDDSKNTAYLQMNNLKTEDTAVYY CVRHGNFGNSYVSWFAYWGQGTLLTVSSGG GGSQVQLKQSGPGLVQPSQSLSTCTVSGFSLT NYGVHWVRQSPGKGLEWLGVIWSSGGNTDYN TPFTSRLSINKDNSKSQVFFKMNSLQSQDTAIY YCARALTYDYEFAYWGQGTLLTVSAASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTV PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC	32

Ab-3 LC	DILLTQSPVILSVSPGERVSFSCRASQSIGTNIH WYQQRNNGSPRLLIK Y ASESISGIPSRFSGSGSG TDFTLSINSVESEDIADYYCQONNNWPTTFGA GTKLELKRTVAAPSVFIFPPSDEQLKSGTASVV CLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYLSSTLTLSKADYEKHKVYACEVT HQGLSSPVTKSFNRGEC	26
Ab-3 HC	QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSN YANWVQKPGQAPRGLIGGTNKRAPGTPARFS GSLGGAALTLSGVQPEDEAEYYC ALWYSN LWVFGGGTKLTVLGGGSGGGGSGGGGSEVQ LVESGGGLVQPGGSLKLSAASGFTFNTYAMN WVRQAPGKGLEWVARIRSKYNNYATYYADS VKDRFTISRDDSKNTAYLQMNNLKTEDTAVYY CVRHGNFGNSYVSWFAYWGQGLVTVSSGG GGSQVQLKQSGPGLVQPSQSLITCTVSGFSLT NYGVHWVRQSPGKGLEWLGVIWSSGNTDYN TPFTSRLSINKDNSKSQVFFKMNSLQSDTAIY YCARALTYDYEFAYWGQGLVTVSAASTKG PSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTV PSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC	33

[00313] Ab-1, Ab-2, and Ab-3 binding to EGFR and CD3 was evaluated using enzyme linked immunosorbent assays (ELISAs). Biotinylated peptides were captured on neutravidin coated plates. Polypeptide complex molecules diluted in buffer were added to the antigen coated plates. Bound polypeptide complex was detected using a standard horseradish peroxidase conjugated secondary antibody. The concentration of polypeptide complex required to achieve 50% maximal signal (EC50) was calculated using Graphpad Prism software. Data is seen in Fig. 2 for Ab-1 and Ab-2 binding to EGFR and in Fig. 3 for Ab-3 binding to EGFR. Data is seen in Fig. 4 for Ab-1 and Ab-2 binding to CD3 and in Fig. 5 for Ab-3 binding to CD3. EC50 data is seen in Table 10.

Table 10.

Polypeptide	EC50 nM	
	EGFR	CD3
Ab-1	0.05	0.05
Ab-2	0.05	0.08
Ab-3	0.19	0.04

Example 2: Binding to Human vs Cyno EGFR and CD3

[00314] Kinetic binding of Ab-1 molecules to human and cynomolgus monkey EGFR was evaluated by bio-layer interferometry using an Octet RED96 instrument. Briefly, biosensors were loaded with antigen and baselined in buffer. Polypeptide molecules were titrated in solution at 50nM, 25nM, 12.5nM, and 6.25nM then associated onto the antigen loaded sensors. After a short association period, sensors were transferred into buffer and the dissociation of bound polypeptide molecules was measured. The timing and steps of the

experiment are shown Table 11. Association and dissociation signals were recorded in real time and analyzed using a 1:1 binding model within the instrument software. Analysis using a 1:1 binding model enabled the calculation of the on and off rate constants as well as affinity, K_D . Off rate constants were converted to half-life shown in Fig. 6.

Table 11.

Step	Time	pH
Baseline: Octet buffer	60 sec	pH 7.4
Load: 15 nM human EGFR 15 nM cyno EGFR	300 sec	pH 7.4
Baseline: Octet buffer	300 sec	pH 7.4
Association: • 50nM Ab-1 • 25 nM Ab-1 • 12.5 nM Ab-1 • 6.25 nM Ab-1	300sec	pH 7.4
Dissociation: Octet Buffer	900sec	pH 7.4

[00315] Kinetic binding of polypeptide molecules to human and cyno CD3 was evaluated by bio-layer interferometry using an Octet RED96 instrument. Briefly, biosensors were loaded with antigen and baselined in buffer. Polypeptide molecules were titrated in solution at 50nM, 25nM, 12.5nM, and 6.25nM then associated onto the antigen loaded sensors. After a short association period, sensors were transferred into buffer and the dissociation of bound polypeptide molecules was measured. The timing and steps of the experiment are shown in Table 12. Association and dissociation signals were recorded in real time and analyzed using a 1:1 binding model within the instrument software. Analysis using a 1:1 binding model enabled the calculation of the on and off rate constants as well as affinity, K_D . Off rate constants were converted to half-life shown in Fig. 7.

Table 12.

Step	Time	pH
Baseline: Octet buffer	60 sec	pH 7.4
Load: • 15 nM human CD3e • 15 nM cyno CD3e	300 sec	pH 7.4
Baseline: Octet buffer	300 sec	pH 7.4
Association in Octet buffer	300 sec	pH 7.4

• 50 nM Ab-1 • 25 nM Ab-1 • 12.5 nM Ab-1 • 6.25 nM Ab-1		
Dissociation: Octet buffer	900 sec	pH 7.4

[00316] The polypeptide complex molecules were evaluated for their ability to bind human and cynomolgus monkey antigens, EGFR or CD3, in a standard enzyme linked immunosorbent assay (ELISA) format. Briefly, antigens fused to a human Fc domain were directly coated on high binding ELISA plates. Polypeptide complex molecules diluted in buffer were then added to the antigen coated plates. Bound polypeptide complex was detected using a standard horse radish peroxidase conjugate secondary antibody. Binding curves are shown in **Fig. 8** (human EGFR), **Fig. 9** (cyno EGFR), **Fig. 10** (human CD3), and **Fig. 11** (cyno CD3). The concentration of polypeptide complex required to achieve 50% maximal signal (EC50) (Table 13) was calculated using Graphpad Prism software.

Table 13.

	EC50 (nM)			
	Human EGFR	Cyno EGFR	Human CD3	Cyno CD3
Ab-1	0.55	0.54	0.72	0.71
Ab-2	0.45	0.45	0.78	0.71

Example 2: In vitro Efficacy of EGFR Polypeptide Complexes

[00317] Polypeptide complexes were evaluated in a functional in vitro tumor cell killing assay using the EGFR positive tumor cell lines HCT116 and A431. Tumor cell killing was measured using an xCelligence real time cell analyzer from Agilent that relies on sensor impedance measurements (cell index) that increased as tumor cells adhere, spread, and expand on the surface of the sensor. Likewise, as the tumor cells were killed the impedance decreased. 10,000 tumor cells were added per well and allowed to adhere overnight on a 96 well E-Plate. The following day polypeptide complexes titrated in human serum supplemented medium along with 30,000 CD8+ T cells were added to the wells. Cell index measurements were taken every 10 minutes for an additional 72 hours. The cell index times number of hours (tumor cell growth kinetics) was then plotted versus concentration of polypeptide complex where the concentration required to reduce the tumor growth 50% (IC50) was calculated using Graphpad Prism software. Data are shown in **Fig. 12** (Ab-3, HCT116 cells), **Fig. 13** (Ab-2, HCT116 cells), **Fig. 14** (Ab-1, HCT116 cells), and **Fig. 15** (Ab-1, A431 cells) and Table 14.

Table 14.

Antibody	IC50 (pM) HCT116 Cells	IC50 (pM) A431 cells
Ab-1	0.43	0.18
Ab-2	0.53	ND
Ab-3	0.47	ND

Example 3: Pharmacokinetics in Cynomolgus Monkey After IV Bolus Administration of EGFR Polypeptide Complex Ab-3

[00318] Pharmacokinetics and exploratory safety of polypeptide molecules were evaluated in cynomolgus monkeys for Ab-3. Briefly, cynomolgus monkeys of approximately 3kg bodyweight were administered polypeptides as an IV bolus and observed daily for signs of adverse events. No in-life adverse events were observed. After dosing, blood was collected in K2 EDTA tubes at specific timepoints and processed to plasma. Plasma was stored frozen until analysis. Concentration of polypeptide molecules in plasma was measured via standard ELISA techniques relative to a reference standard diluted in control cyno plasma. Plasma concentration curves were fit to a standard two phase exponential equation representing distribution and elimination phases (Fig. 16). Fitting of pharmacokinetics enabled the calculation of C_{max}, half-life, volume of distribution, clearance, and 7 day area under the curve (AUC) shown in Table 15.

Table 15.

	Ab-3 (10 µg/kg)	Ab-3 (3µ/kg)
C _{Max} (nM)	1.66	0.17
t _{1/2} (hr)	1.30	0.32
Vd (L)	0.24	0.68
VSS (L)	1.08	0.63
CL (ml/hr/kg)	41.72	500.62
BW (kg)	3.00	3.00
7 day AUS (nM min)	75	5

Example 4: Cytokine Release in Cynomolgus Monkey After IV Bolus Administration of EGFR Polypeptide Complex Ab-3

Cytokine release after Ab-3 administration by IV bolus was evaluated in cynomolgus monkeys. Briefly, cynomolgus monkeys of approximately 3kg bodyweight were administered polypeptides as an IV bolus and observed daily for signs of adverse events. No in-life adverse events were observed. After dosing, blood was collected in K2 EDTA tubes at specific timepoints and processed to plasma. Plasma was stored frozen until analysis. Plasma samples were analyzed for cytokines using a non-human primate cytometric Th1/Th2 bead array kit from BD biosciences following the manufacturer's instructions. Interferon gamma, tumor necrosis

factor alpha, interleukin 6, interleukin 5, interleukin 4, and interleukin 2 levels in plasma were calculated relative to reference standards provided with the bead array kit (**Fig. 17**).

Example 5: Serum Liver Enzymes in Cynomolgus Monkey After IV Bolus Administration of EGFR Polypeptide Complex Ab-3

[00319] Systemic liver enzymes after Ab-3 administration by IV bolus was evaluated in cynomolgus monkeys. Briefly, cynomolgus monkeys of approximately 3kg bodyweight were administered polypeptides as an IV bolus and observed daily for signs of adverse events. No in-life adverse events were observed. After dosing, blood was collected in K2 EDTA tubes at specific timepoints and processed to plasma. Plasma was stored frozen until analysis. Plasma samples were analyzed for the presence of liver enzymes aspartate transaminase (AST) and alanine aminotransferase (ALT) as signs of potential liver toxicity. AST and ALT levels were remained within the normal ranges for all timepoints tested after dosing suggesting a lack of liver toxicity. AST and ALT were quantified following the instructions provided in a commercially available kit from Millipore. AST and ALT levels were calculated according to manufacturer's instructions relative to a positive control reference standard (**Fig. 18**).

Example 6: EGFR Polypeptide Complex Binding

[00320] Polypeptide complex molecules Ab-1 and Ab-4 were evaluated for their ability to bind EGFR and CD3ε. Ab-4 and Ab-1 have different connection orientations between anti-CD3 scFv and anti-EGFR Fab. In Ab-4, the anti-CD3 scFv light chain is connected to the anti-EGFR Fab light chain (form Vl, **Fig. 1B**). In Ab-1, the anti-CD3 scFv light chain is connected to the anti-EGFR Fab heavy chain (form Vh, **Fig. 1A**). The sequence of Ab-4 is provided in **Table 16**.

Table 16. Ab-4 Sequence

Antibody sequence that binds to EGFR and CD3		
Ab-4 HC	QVQLKQSGPGLVQPSQSL SITCTVSGFSLTNYG VHWVRQSPGKGLEWLGVIWSGGNTDYNTPT SRLSINKDNSKSQVFFKMNSLQSQDTAIYYCAR ALTYDYEFAYWGQGLVTVSAASTKGPSVFP LAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVTVPSSSL GTQTYICNVNHKPSNTKVDKKVEPKSC	27
Ab-4 LC	EVQLVESGGGLVQPGGSLKLSAASGFTFNKY AMNWVRQAPGKGLEWVARIRSKYNNYATYY ADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGLVTVSS GGGSGGGGSGGGGSGTQVVTQEPSTVSPGGT VTLTCGSSTGAVTSGNYPNWWVQKPGQAPRG LIGGTKFLAPGTPARFSGSLLGGKAALTLGVQ PEDEAEYYCVLWYSNRWVFGGGTKLTVLGGG GSQILLTQSPVILSVSPGERVSFSCRASQSIGTNI HWYQQR TNGSPRLLIK YASESISGIPSRFSGSGS GTDFTLSINSVESEDIADYYCQONNNWPTTFG AGTKLELKRTVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPREAKVQWKVDNALQSGNSQESV	34

	TEQDSKDSTYLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC	
--	--	--

[00321] Binding was measured using a standard ELISA format. Briefly, biotinylated antigen was captured on neutravidin coated plates. Polypeptide complex molecules diluted in buffer were then added to the antigen coated plates. Bound polypeptide complex was detected using a standard horse radish peroxidase conjugate secondary antibody. The concentration of polypeptide complex required to achieve 50% maximal signal (EC_{50}) was calculated using Graphpad Prism software. Binding curves are shown in **Fig. 19** for Ab-4 and Ab-1 binding to EGFR, and in **Fig. 20** for Ab-4 and Ab-1 binding to CD3 ϵ . EC_{50} data is shown in Table 17.

Table 17.

Polypeptide	EC_{50} nM	
	EGFR	CD3
Ab-1	0.06	0.04
Ab-4	0.46	0.25

Example 7: In vitro Efficacy of EGFR Polypeptide Complexes

[00322] Polypeptide complexes Ab-1 and Ab-4 were evaluated in a functional in vitro tumor cell killing assay using the EGFR positive tumor cell line HCT116. Tumor cell killing was measured using an xCelligence real time cell analyzer from Agilent that relies on sensor impedance measurements (cell index) that increased as tumor cells adhere, spread, and expand on the surface of the sensor. Likewise, as the tumor cells were killed the impedance decreased. 10,000 tumor cells were added per well and allowed to adhere overnight on a 96 well E-Plate. The following day polypeptide complexes titrated in human serum supplemented medium along with 30,000 CD8+ T cells were added to the wells. Cell index measurements were taken every 10 minutes for an additional 72 hours. The cell index times number of hours (tumor cell growth kinetics) was then plotted versus concentration of polypeptide complex where the concentration required to reduce the tumor growth 50% (IC_{50}) was calculated using Graphpad Prism software. Tumor cell killing data is shown in **Fig. 21**. IC_{50} data is provided in Table 18.

Table 18.

Antibody	IC_{50} (pM) HCT116 Cells
Ab-1	0.5
Ab-4	9.0

Example 8: Pharmacokinetics in Cynomolgus Monkey After Continuous IV Infusion of EGFR Polypeptide Complex Ab-1

[00323] Pharmacokinetics and exploratory safety of polypeptide molecules were evaluated in cynomolgus monkeys for Ab-1. Briefly, cynomolgus monkeys of approximately 3kg bodyweight were implanted with an infusion pump subcutaneously. Two weeks later the pump was filled with polypeptide dosing solution and

administered via constant infusion. Three different concentrations were studied, 5ug/kg/day, 15ug/kg/day, and 30ug/kg/day. After dosing started, blood was collected in K2 EDTA tubes at specific timepoints and processed to plasma. Plasma was stored frozen until analysis. Concentration of polypeptide molecules in plasma was measured via standard ELISA techniques relative to a reference standard diluted in control cyno plasma. Plasma concentration curves were plotted overtime as shown in **Fig. 22** and calculated C_{MAX} values are provided in **Tables 19-21**.

Table 19.

	Ab-1 5ug/kg/day	Units	Tolerated/Not tolerated dose?
C_{MAX}	0.025	nM	Tolerated

Table 20.

	Ab-1 15ug/kg/day	Units	Tolerated/Not tolerated dose?
C_{MAX}	0.031	nM	Tolerated

Table 21.

	Ab-1 30ug/kg/day	Units	Tolerated/Not tolerated dose?
C_{MAX}	0.208	nM	Not tolerated

Example 9: Cytokine Release in Cynomolgus Monkey After Continuous IV Infusion of EGFR Polypeptide Complex Ab-1

[00324] Cytokine release after Ab-1 administration by continuous IV infusion was evaluated in cynomolgus monkeys. Briefly, cynomolgus monkeys of approximately 3kg bodyweight were implanted with an infusion pump subcutaneously. Two weeks later the pump was filled with polypeptide dosing solution and administered via constant infusion. Three different concentrations were studied, 5ug/kg/day, 15ug/kg/day, and 30ug/kg/day. After dosing started, blood was collected in K2 EDTA tubes at specific timepoints and processed to plasma. Plasma samples were analyzed for cytokines using a non-human primate cytometric Th1/Th2 bead array kit from BD biosciences following the manufacturer's instructions. Interferon gamma, tumor necrosis factor alpha, interleukin 6, interleukin 5, interleukin 4, and interleukin 2 levels in plasma were calculated relative to reference standards provided with the bead array kit. **Figs. 23A-23B** demonstrate plasma IL-6 levels plotted over time for the three different concentrations of Ab-1.

CLAIMS

WHAT IS CLAIMED IS:

1. An isolated polypeptide complex according to the following formula:

A-L-B

(Formula I)

wherein

A comprises a single chain variable fragment (scFv) that binds to CD3;

B comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, and HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3; and

L comprises a linker that connects A to B.

2. The isolated polypeptide complex according to claim 1, wherein the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21, LC-CDR2: SEQ ID NO: 22, and LC-CDR3: SEQ ID NO: 23, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

3. The isolated polypeptide complex according to claim 1, wherein the scFv comprises a scFv light chain variable domain and a scFv heavy chain variable domain.

4. The isolated polypeptide complex according to claim 3, wherein the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise either HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 3; or HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3.

5. The isolated polypeptide complex according to claim 3, wherein the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise either LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8; or

LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11 and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

6. The isolated polypeptide complex according to claim 1, wherein the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27.

7. The isolated polypeptide complex according to claim 1, wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 25 or 27.

8. The isolated polypeptide complex according to claim 7, wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27.

9. The isolated polypeptide complex according to claim 7, wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27.

10. The isolated polypeptide complex according to claim 1, wherein the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 25 or 27.

11. The isolated polypeptide complex according to claim 2, wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24 or 26.

12. The isolated polypeptide complex according to claim 2, wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 or 26.

13. The isolated polypeptide complex according to claim 2, wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26.

14. The isolated polypeptide complex according to claim 2, wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26.

15. The isolated polypeptide complex according to claim 2, wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24 or 26.
16. The isolated polypeptide complex according to claim 3, wherein the scFv heavy chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 13 or 16.
17. The isolated polypeptide complex according to claim 3, wherein the scFv heavy chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 13 or 16.
18. The isolated polypeptide complex according to claim 3, wherein the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16.
19. The isolated polypeptide complex according to claim 3, wherein the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16.
20. The isolated polypeptide complex according to claim 3, wherein the scFv heavy chain variable domain comprises an amino acid sequence according to SEQ ID NO: 13 or 16.
21. The isolated polypeptide complex according to claim 3, wherein the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 12 or 15.
22. The isolated polypeptide complex according to claim 3, wherein the scFv light chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 12 or 15.
23. The isolated polypeptide complex according to claim 22, wherein the scFv light chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15.
24. The isolated polypeptide complex according to claim 22, wherein the scFv light chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15.

25. The isolated polypeptide complex according to claim 3, wherein the scFv light chain variable domain comprises an amino acid sequence according to SEQ ID NO: 12 or 15.
26. The isolated polypeptide complex according to claim 3, wherein the scFv comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17.
27. The isolated polypeptide complex according to claim 3, wherein the scFv comprises an amino acid sequence of at least 150 consecutive amino acid residues of SEQ ID NO: 14 or 17.
28. The isolated polypeptide complex according to claim 27, wherein the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17.
29. The isolated polypeptide complex according to claim 27, wherein the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17 and has at least 80% sequence identity to the at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17.
30. The isolated polypeptide complex according to claim 3, wherein the scFv comprises an amino acid sequence according to SEQ ID NO: 14 or 17.
31. The isolated polypeptide complex according to claim 1, wherein the linker connects the C-terminus of A to an N-terminus of B.
32. The isolated polypeptide complex according to claim 1, wherein the linker connects the N-terminus of A to a C-terminus of B.
33. The isolated polypeptide complex according to claim 31, wherein the linker connects the C-terminus of A to the N-terminus of the Fab heavy chain polypeptide.
34. The isolated polypeptide complex according to claim 32, wherein the linker connects the N-terminus of A to the C-terminus of the Fab heavy chain polypeptide.
35. The isolated polypeptide complex according to claim 31, wherein the linker connects the C-terminus of A to the N-terminus of the Fab light chain polypeptide.
36. The isolated polypeptide complex according to claim 32, wherein the linker connects the N-terminus of A to the C-terminus of the Fab light chain polypeptide.
37. The isolated polypeptide complex according to claim 3, wherein the linker connects the Fab light chain polypeptide to the scFv light chain variable domain.

38. The isolated polypeptide complex according to claim 3, wherein the linker connects the Fab light chain polypeptide to the scFv heavy chain variable domain.
39. The isolated polypeptide complex according to claim 3, wherein the linker connects the Fab heavy chain polypeptide to the scFv light chain variable domain.
40. The isolated polypeptide complex according to claim 3, wherein the linker connects the Fab heavy chain polypeptide to the scFv heavy chain variable domain.
41. The isolated polypeptide complex according to claim 36, wherein the linker connects the Fab light chain polypeptide to the N-terminus of the scFv light chain variable domain.
42. The isolated polypeptide complex according to claim 35, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain.
43. The isolated polypeptide complex according to claim 36, wherein the linker connects the Fab light chain polypeptide to the N-terminus of the scFv heavy chain variable domain.
44. The isolated polypeptide complex according to claim 35, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv heavy chain variable domain.
45. The isolated polypeptide complex according to claim 34, wherein the linker connects the Fab heavy chain polypeptide to the N-terminus of the scFv light chain variable domain.
46. The isolated polypeptide complex according to claim 33, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain.
47. The isolated polypeptide complex according to claim 34, wherein the linker connects the Fab heavy chain polypeptide to the N-terminus of the scFv heavy chain variable domain.
48. The isolated polypeptide complex according to claim 33, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv heavy chain variable domain.
49. The isolated polypeptide complex according to claim 1, wherein the linker is at least 5 amino acids in length.
50. The isolated polypeptide complex according to claim 49, wherein the linker is no more than 30 amino acids in length.
51. The isolated polypeptide complex according to claim 1, wherein the linker is at least 5 amino acids and no more than 30 amino acids in length.

52. The isolated polypeptide complex according to claim 1, wherein the linker is 5 amino acids in length.
53. The isolated polypeptide complex according to claim 1, wherein the linker is 15 amino acids in length.
54. The isolated polypeptide complex according to claim 1, wherein the linker comprises an amino acid sequence of SEQ ID NO: 28 (GGGGSGGGSGGGGS), SEQ ID NO: 29 (GGGGS), or SEQ ID NO: 30 (GGGGSGGGGS).
55. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 31.
56. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 31.
57. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31.
58. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 31.

59. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 31.

60. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 32.

61. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 32.

62. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32.

63. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 32.

64. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab

light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 32.

65. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 33.

66. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 33.

67. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33.

68. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 33.

69. The isolated polypeptide complex according to claim 46, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 26, and an amino acid

sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 33.

70. The isolated polypeptide complex according to claim 42, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 34.


71. The isolated polypeptide complex according to claim 42, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 34.

72. The isolated polypeptide complex according to claim 42, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34.

73. The isolated polypeptide complex according to claim 42, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 27 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 27 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 34.

74. The isolated polypeptide complex according to claim 42, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 34.

75. An isolated polypeptide complex according to the following formula:



wherein

A comprises a single chain variable fragment (scFv) that binds to CD3;

D comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR; and

L comprises a linker that connects the C-terminus of A to an N-terminus of D.

76. The isolated polypeptide complex according to claim 75, wherein the Fab or Fab' comprises a Fab light chain polypeptide chain comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain.

77. The isolated polypeptide complex according to claim 76, wherein the scFv comprises a scFv light chain variable domain and a scFv heavy chain variable domain.

78. The isolated polypeptide complex according to claim 77, wherein the linker connects the C-terminus of A to the N-terminus of the Fab heavy chain polypeptide.

79. The isolated polypeptide complex according to claim 77, wherein the linker connects the C-terminus of A to the N-terminus of the Fab light chain polypeptide.

80. The isolated polypeptide complex according to claim 79, wherein the linker connects the C-terminus of the scFv light chain variable domain to the N-terminus of the Fab heavy chain polypeptide.

81. The isolated polypeptide complex according to claim 79, wherein the linker connects the C-terminus of scFv light chain variable domain to the N-terminus of the Fab light chain polypeptide.

82. The isolated polypeptide complex according to claim 79, wherein the linker connects the C-terminus of the scFv heavy chain variable domain to the N-terminus of the Fab heavy chain polypeptide.

83. The isolated polypeptide complex according to claim 79, wherein the linker connects the C-terminus of scFv heavy chain variable domain to the N-terminus of the Fab light chain polypeptide.

84. The isolated polypeptide complex according to claim 77, wherein the Fab heavy chain variable domain comprises complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, HC-CDR3: SEQ ID NO: 20, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3.

85. The isolated polypeptide complex according to claim 77, wherein the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21; LC-CDR2: SEQ ID NO: 22; and LC-CDR3: SEQ ID NO: 23, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

86. The isolated polypeptide complex according to claim 77, wherein the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: either HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, HC-CDR3: SEQ ID NO: 3; or HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the HC-CDR1, HC-CDR2, or HC-CDR3.

87. The isolated polypeptide complex according to claim 77, wherein the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise either LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8; or LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11, and wherein the CDRs comprise from 0-2 amino acid modifications in at least one of the LC-CDR1, LC-CDR2, or LC-CDR3.

88. The isolated polypeptide complex according to claim 77, wherein the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 25 or 27.

89. The isolated polypeptide complex according to claim 77, wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 25 or 27.

90. The isolated polypeptide complex according to claim 89, wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27.

91. The isolated polypeptide complex according to claim 89, wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 25 or 27.

92. The isolated polypeptide complex according to claim 77, wherein the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 25 or 27.

93. The isolated polypeptide complex according to claim 77, wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24 or 26.

94. The isolated polypeptide complex according to claim 77, wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24 or 26.

95. The isolated polypeptide complex according to claim 94, wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26.

96. The isolated polypeptide complex according to claim 94, wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 or 26.

97. The isolated polypeptide complex according to claim 77, wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24 or 26.

98. The isolated polypeptide complex according to claim 77, wherein the scFv heavy chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 13 or 16.

99. The isolated polypeptide complex according to claim 77, wherein the scFv heavy chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 13 or 16.

100. The isolated polypeptide complex according to claim 99, wherein the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16.

101. The isolated polypeptide complex according to claim 99, wherein the scFv heavy chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 13 or 16.

102. The isolated polypeptide complex according to claim 77, wherein the scFv heavy chain variable domain comprises an amino acid sequence according to SEQ ID NO: 13 or 16.

103. The isolated polypeptide complex according to claim 77, wherein the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 12 or 15.

104. The isolated polypeptide complex according to claim 77, wherein the scFv light chain variable domain comprises an amino acid sequence of at least 50 consecutive amino acid residues of SEQ ID NO: 12 or 15.

105. The isolated polypeptide complex according to claim 104, wherein the scFv light chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15.

106. The isolated polypeptide complex according to claim 104, wherein the scFv light chain variable domain comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15 and has at least 80% sequence identity to the at least 100 consecutive amino acid residues of SEQ ID NO: 12 or 15.

107. The isolated polypeptide complex according to claim 77, wherein the scFv light chain variable domain comprises an amino acid sequence according to SEQ ID NO: 12 or 15.

108. The isolated polypeptide complex according to claim 77, wherein the scFv comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 14 or 17.

109. The isolated polypeptide complex according to claim 77, wherein the scFv comprises an amino acid sequence of at least 150 consecutive amino acid residues of SEQ ID NO: 14 or 17.

110. The isolated polypeptide complex according to claim 109, wherein the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17.

111. The isolated polypeptide complex according to claim 109, wherein the scFv comprises an amino acid sequence of at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17 and has at least 80% sequence identity to the at least 225 consecutive amino acid residues of SEQ ID NO: 14 or 17.

112. The isolated polypeptide complex according to claim 77, wherein the scFv comprises an amino acid sequence according to SEQ ID NO: 14 or 17.

113. The isolated polypeptide complex according to claim 77, wherein the linker is at least 5 amino acids in length.

114. The isolated polypeptide complex according to claim 113, wherein the linker is no more than 30 amino acids in length.

115. The isolated polypeptide complex according to claim 114, wherein the linker is at least 5 amino acids and no more than 30 amino acids in length.

116. The isolated polypeptide complex according to claim 115, wherein the linker is 5 amino acids in length.

117. The isolated polypeptide complex according to claim 115, wherein the linker is 15 amino acids in length.

118. The isolated polypeptide complex according to claim 115, wherein the linker comprises an amino acid sequence of SEQ ID NO: 28 (GGGGSGGGSGGGGS), SEQ ID NO: 29 (GGGGS), or SEQ ID NO: 30 (GGGGSGGGGS).

119. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 31.

120. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 31.

121. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31.

122. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 31 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 31.

123. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv heavy chain variable domain comprises an amino acid sequence of SEQ ID NO: 31.

124. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 32.

125. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 32.

126. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32.

127. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab

light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 24 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 24 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 32 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 32.

128. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 24, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 32.

129. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 33.

130. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 33.

131. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33.

132. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 26 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of

SEQ ID NO: 26 and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 33 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 33.

133. The isolated polypeptide complex according to claim 80, wherein the linker connects the Fab heavy chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 26, and an amino acid sequence of the Fab heavy chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 33.

134. The isolated polypeptide complex according to claim 81, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence that has at least 80% sequence identity to the amino acid sequence according to SEQ ID NO: 34.

135. The isolated polypeptide complex according to claim 81, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 100 consecutive amino acid residues of SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 400 consecutive amino acid residues of SEQ ID NO: 34.

136. The isolated polypeptide complex according to claim 81, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab light heavy polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34.

137. The isolated polypeptide complex according to claim 81, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence of at least 200 consecutive amino acid residues of SEQ ID NO: 27 and has at least 80% sequence identity to the at least 200 consecutive amino acid residues of SEQ ID NO: 27 and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-

terminus of the scFv light chain variable domain comprises an amino acid sequence of at least 450 consecutive amino acid residues of SEQ ID NO: 34 and has at least 80% sequence identity to the at least 450 consecutive amino acid residues of SEQ ID NO: 34.

138. The isolated polypeptide complex according to claim 81, wherein the linker connects the Fab light chain polypeptide to the C-terminus of the scFv light chain variable domain and wherein the Fab heavy chain polypeptide comprises an amino acid sequence according to SEQ ID NO: 27, and an amino acid sequence of the Fab light chain polypeptide that is connected to the C-terminus of the scFv light chain variable domain comprises an amino acid sequence of SEQ ID NO: 34.

139. The isolated polypeptide complex according to claim 77, wherein the Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, HC-CDR3: SEQ ID NO: 20; the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21; LC-CDR2: SEQ ID NO: 22; and LC-CDR3: SEQ ID NO: 23; the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: either HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, HC-CDR3: SEQ ID NO: 3; or HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5; the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise either LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8; or LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11.

140. The isolated polypeptide complex according to claim 77, wherein the Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, HC-CDR3: SEQ ID NO: 20; the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21; LC-CDR2: SEQ ID NO: 22; and LC-CDR3: SEQ ID NO: 23; the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 1, HC-CDR2: SEQ ID NO: 2, HC-CDR3: SEQ ID NO: 3; the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-

CDR3 of the scFv light chain variable domain comprise LC-CDR1: SEQ ID NO: 6, LC-CDR2: SEQ ID NO: 7, and LC-CDR3: SEQ ID NO: 8.

141. The isolated polypeptide complex according to claim 77, wherein the Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the Fab heavy chain variable domain comprise HC-CDR1: SEQ ID NO: 18, HC-CDR2: SEQ ID NO: 19, HC-CDR3: SEQ ID NO: 20; the Fab light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the Fab light chain variable domain comprise LC-CDR1: SEQ ID NO: 21; LC-CDR2: SEQ ID NO: 22; and LC-CDR3: SEQ ID NO: 23; the scFv heavy chain variable domain comprises complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, the HC-CDR2, and the HC-CDR3 of the scFv heavy chain variable domain comprise: HC-CDR1: SEQ ID NO: 4, HC-CDR2: SEQ ID NO: 2, and HC-CDR3: SEQ ID NO: 5; the scFv light chain variable domain comprises complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, the LC-CDR2, and the LC-CDR3 of the scFv light chain variable domain comprise LC-CDR1: SEQ ID NO: 9, LC-CDR2: SEQ ID NO: 10, and LC-CDR3: SEQ ID NO: 11.

142. A pharmaceutical composition comprising:

- (i) the isolated polypeptide complex according to claim 1-138; and
- (ii) a pharmaceutically acceptable excipient.

143. An isolated recombinant nucleic acid molecule encoding a polypeptide of the polypeptide complex according to claim 1-141.




Fig. 1A




Fig. 1B

EGFR ELISA




Fig. 2

EGFR ELISA




Fig. 3

CD3e ELISA




Fig. 4

CD3e ELISA




Fig. 5




Fig. 6




Fig. 7

Human EGFR ELISA




Fig. 8

Cyno EGFR ELISA




Fig. 9

Human CD3e ELISA




Fig. 10

Cyno CD3e ELISA




Fig. 11

CD8+ T-cells : HCT116 (3:1) for 72hours




Fig. 12

CD8+ T-cells : HCT116 (3:1) for 72hours




Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 17




Fig. 18




Fig. 19




Fig. 20




Fig. 21




Fig. 22




Fig. 23A




Fig. 23B

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2022/028579

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - INV. - C07K 16/46; C07K 16/24; C07K 16/28 (2022.01)

ADD.

CPC - INV. - C07K 16/46; C07K 16/24; C07K 16/28 (2022.08)

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2015/0232557 A1 (EMERGENT PRODUCT DEVELOPMENT SEATTLE LLC) 20 August 2015 (20.08.2015) entire document	1-25, 31-54
A	US 2016/0289341 A1 (EPIMAB BIOTHERAPEUTICS INC.) 06 October 2016 (06.10.2016) entire document	1-25, 31-54
A	US 2004/0229310 A1 (SIMMONS) 18 November 2004 (18.11.2004) entire document	1-25, 31-54

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

19 September 2022

Date of mailing of the international search report

OCT 06 2022

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Taina Matos

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2022/028579

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:

- a. ☐ forming part of the international application as filed:
 - ☐ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
- b. ☐ furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
- c. ☒ furnished subsequent to the international filing date for the purposes of international search only:
 - ☒ in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).

2. ☒ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

SEQ ID NOs: 12, 13, 24, 25, and 28 were searched.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2022/028579

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 142, 143
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
See extra sheet(s).

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-25, 31-54

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2022/028579

Continued from Box No. III Observations where unity of invention is lacking

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees need to be paid.

Group I+: claims 1-74 are drawn to isolated polypeptide complexes according to Formula I, pharmaceutical compositions thereof, and isolated recombinant nucleic acid molecules encoding a polypeptide thereof.

Group II+: claims 75-141 are drawn to isolated polypeptide complexes according to Formula II, pharmaceutical compositions thereof, and isolated recombinant nucleic acid molecules encoding a polypeptide thereof.

The first invention of Group I+ is restricted to an isolated polypeptide complex according to the following formula: A-L-B (Formula I) wherein A comprises a single chain variable fragment (scFv) that binds to CD3, wherein the scFv comprises a scFv light chain variable domain selected to be SEQ ID NO: 12 and a scFv heavy chain variable domain selected to be SEQ ID NO: 13; B comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR, wherein the Fab or Fab' comprises a Fab light chain polypeptide comprising a Fab light chain variable domain selected to be SEQ ID NO: 24 and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain selected to be SEQ ID NO: 25; and L comprises a linker that connects A to B selected to be SEQ ID NO: 28, pharmaceutical compositions thereof, and isolated recombinant nucleic acid molecules encoding a polypeptide thereof. It is believed that claims 1-25, and 31-54 read on this first named invention and thus these claims will be searched without fee to the extent that they read on SEQ ID NOs: 12, 13, 24, 25, and 28.

The first invention of Group II+ is restricted to isolated polypeptide complex according to the following formula: A-L-D (Formula II) wherein A comprises a single chain variable fragment (scFv) that binds to CD3, wherein the scFv comprises a scFv light chain variable domain selected to be SEQ ID NO: 12 and a scFv heavy chain variable domain selected to be SEQ ID NO: 13; D comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR, wherein the Fab or Fab' comprises a Fab light chain polypeptide comprising a Fab light chain variable domain selected to be SEQ ID NO: 24 and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain selected to be SEQ ID NO: 25; and L comprises a linker that connects the C-terminus of A to an N-terminus of D selected to be SEQ ID NO: 28, pharmaceutical compositions thereof, and isolated recombinant nucleic acid molecules encoding a polypeptide thereof.

Applicant is invited to elect additional isolated polypeptide complexes, and their respective, corresponding, SEQ ID NOs to be searched in a specific combination by paying additional fee for each set of election. An exemplary election would be an isolated polypeptide complex according to the following formula: A-L-B (Formula I) wherein A comprises a single chain variable fragment (scFv) that binds to CD3; B comprises an antigen binding fragment (Fab) or Fab' that binds to EGFR wherein the Fab or Fab' comprises a Fab light chain polypeptide comprising a Fab light chain variable domain and a Fab heavy chain polypeptide comprising a Fab heavy chain variable domain comprising complementarity determining region (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3; and L comprises a linker that connects A to B, pharmaceutical compositions thereof, and isolated recombinant nucleic acid molecules encoding a polypeptide thereof. Additional isolated polypeptide complexes, and their respective, corresponding, SEQ ID NOs will be searched upon the payment of additional fees. Applicants must specify the claims that read on any additional elected inventions. Applicants must further indicate, if applicable, the claims which read on the first named invention if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched/examined.

The inventions listed in Groups I+ and II+ do not relate to a single general inventive concept under PCT Rule 13.1, because under PCT Rule 13.2 they lack the same or corresponding special technical features for the following reasons:

The special technical features of Group I+, isolated polypeptide complexes according to Formula I, pharmaceutical compositions thereof, and isolated recombinant nucleic acid molecules encoding a polypeptide thereof, are not present in Group II+; and the special technical features of Group II+, isolated polypeptide complexes according to Formula II, pharmaceutical compositions thereof, and isolated recombinant nucleic acid molecules encoding a polypeptide thereof, are not present in Group I+.

The Groups I+ and II+ formulas do not share a significant structural element, requiring the selection of alternatives for the A, L, B, D, and accordingly these groups lack unity a priori.

Additionally, even if Groups I+ and II+ were considered to share the technical features of an isolated polypeptide complex having the core structure of Formula I; an isolated polypeptide complex having the core structure of Formula II; a pharmaceutical composition comprising an isolated polypeptide complex and a pharmaceutically acceptable excipient; and an isolated recombinant nucleic acid molecule encoding a polypeptide of a polypeptide complex, these shared technical features do not represent a contribution over the prior art.

Specifically, US 2015/0232557 A1 to Emergent Product Development Seattle LLC (hereinafter, "Seattle") teaches an isolated polypeptide complex having the core structure of Formula I (Para. [0115], invention includes a multispecific binding protein comprising a first binding domain linked via a linker domain to a second binding domain (e.g., a scFv linked via a linker to another scFv). For instance, the invention includes a multispecific binding protein comprising a first binding domain (in VH-linker-VL or VL-linker-VH orientation) linked via a peptide linker domain to a CD3 binding domain; Para. [0116], invention includes essentially any type of polypeptide containing a binding domain or domains as described herein. This includes antibodies, fragments thereof, scFvs, Fabs, di-scFvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments); an isolated polypeptide complex having the core structure of Formula II (Para. [0115], invention includes a multispecific binding protein comprising a first binding domain linked via a linker domain to a second binding domain (e.g., a scFv linked via a linker to another scFv). For instance, the invention includes a multispecific binding protein comprising a first binding domain (in VH-linker-VL or VL-linker-VH orientation) linked via a peptide linker domain to a CD3 binding domain; Para. [0116], invention includes essentially any type of polypeptide containing a binding domain or domains as described herein. This includes antibodies, fragments thereof, scFvs, Fabs, di-scFvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments); a pharmaceutical composition comprising an isolated polypeptide complex and a pharmaceutically acceptable excipient (Para. [0221], invention also includes compositions comprising a CD3 binding polypeptide of the invention and a pharmaceutically acceptable carrier, diluent and/or excipient); and an isolated recombinant nucleic acid molecule encoding a polypeptide of a polypeptide

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2022/028579

complex (Para. [0077], nucleic acid segment encoding a polypeptide of interest; Para. [0201], the invention provides a nucleic acid that encodes an anti-CD19/anti-CD3 bispecific molecule).

The inventions listed in Groups I+ and II+ therefore lack unity under Rule 13 because they do not share a same or corresponding special technical features.